Hims and Hers Health Inc (HIMS)

Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in GermanyJune 2, 2026 5:00 AM
Business Wire Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper’s comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Hers behind it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602926942/en/Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss Since launching in Germany in March 2023, Juniper has grown into a trusted partner for customers seeking evidence-based weight management care in a market where nearly 1 in 5 adults lives with obesity. Juniper’s program, backed by clinical research, pairs personalised treatment with consistent, high-touch clinical support, with a particular focus on connecting women to the weight loss care they need. With the acquisition of Eucalyptus, Hims & Hers brings additional resources and operational expertise to the evidence-based, personalised weight management care Juniper has provided to customers in Germany for years. "Germany has taken meaningful steps to recognize obesity as a chronic disease, but access to effective, personalised care still lags far behind the need," said Andrew Dudum, co-founder and CEO of Hims & Hers. "With this acquisition we can help close that gap at scale, bringing world-class technology and clinical infrastructure to a team that has already earned the trust of people across Germany." To best serve its customers in Germany, Hims & Hers will continue to invest in a local clinical approach, and patients will continue to be connected with providers who are licensed in the local region, understand the healthcare landscape they're navigating, and bring the expertise and clinical rigour this kind of care demands. Hims & Hers also looks forward to potentially introducing new categories of care to the market in the future. As Hims & Hers grows in Germany, continuity of care is a top priority. For customers already receiving care through Juniper, their treatment continues uninterrupted. Joining Hims & Hers gives the team in Germany the backing to keep building on a model that patients have come to trust, with more resources and reach behind it. "Germany has one of the most discerning health consumers in the world, and German patients hold their care to an exceptionally high standard, as they should," said Ryan Nolan, Vice President of International at Juniper. "Hims & Hers brings the ability to meet that standard at scale. Their technology, clinical infrastructure and condition ecosystem means we can deliver a better quality experience to more customers than ever before. We’re excited to continue developing the German telehealth ecosystem into the high touch, compliant clinical care its patients deserve." About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalised care designed for results. For more information, please visit www.hims.com and www.forhers.com. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and “forward-looking information” within the meaning of applicable German securities legislation (collectively, “forward-looking statements”). The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and readers are cautioned not to put undue reliance on them. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “can,” “will,” “likely,” “potential,” “occur,” “projects,” “predicts,” “continue,” “goal,” “objective,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “could,” “should,” “would,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers’ expansion into Germany, the anticipated benefits of the acquisition of Eucalyptus, the expected timing and potential launch of new products or offerings, and assumptions relating to the foregoing. These forward-looking statements are based on management’s current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to the integration of Eucalyptus; our ability to successfully expand into new markets or specialties; our ability to launch new products or offerings on expected timelines or at all; expectations regarding market acceptance, user experience and customer retention; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; the impact of general economic, business, or financial conditions; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission as well as additional risks and uncertainties inherent to Hims & Hers’ business, not currently known by Hims & Hers, that are out of Hims & Hers’ control or that Hims & Hers currently deems to be immaterial, which could also have a material adverse effect on Hims & Hers or on its ability to successfully integrate the acquisition of Eucalyptus. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of the date of this press release. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. If Hims & Hers updates any one or more forward-looking statements, no inference should be drawn that Hims & Hers will make additional updates with respect to those forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260602926942/en/ Press Contact
Susan Cadrecha
press@forhims.com Original: Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany

Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese MarketJune 2, 2026 5:00 AM
Business Wire Closing brings the scale, technology and clinical infrastructure of Hims & Hers to Japan Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, marking a significant milestone in the company's global growth and its formal entry into Japan. This milestone puts the full weight of Hims & Hers’ technology, data, and clinical infrastructure behind a platform that supports weight management care for people in Japan, a market the company approaches with deep respect for its distinct healthcare values and the trust people place in those who serve them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602317273/en/Closing brings the scale, technology and clinical infrastructure of Hims & Hers to Japan Juniper entered Japan in November 2023, and has since become a trusted partner to eligible local customers seeking support in their weight loss journey. In a market where people with weight-related concerns wait an average of six years to seek support for weight loss care, Juniper has built a steady customer base by offering an evidence-based path to care. “In Japan, the need for accessible, quality weight management care has long outpaced what's available. Juniper has already started to change that,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “Hims & Hers is here to accelerate that change, bringing the full scale of our platform behind a team that has already earned the trust of Japanese customers, and a shared commitment to support their lifelong health journeys.” To best serve its customers in Japan, Hims & Hers will continue to invest in a local clinical approach, and customers will continue to be connected with Japanese providers who understand the healthcare landscape they're navigating, and bring the local expertise and clinical rigour this kind of care demands. As Hims & Hers grows in Japan, continuity of care is a top priority. For customers who have received care through Juniper, their treatment continues uninterrupted as the brand grows. Joining Hims & Hers gives the team in Japan the backing to keep building on a model that patients have come to trust, with more resources and reach behind it. “Trust is everything in Japanese healthcare, and it has to be earned,” said Ryan Nolan, Vice President of International at Juniper. “Juniper spent two years doing exactly that, building a standard of weight care that customers here can genuinely rely on. Now through Hims & Hers, we have the global scale and clinical depth to take that work further, providing access to the evidence-based, high-quality, judgment-free care they deserve.” About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalised care designed for results. For more information, please visit www.hims.com and www.forhers.com. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and “forward-looking information” within the meaning of applicable Japanese securities legislation (collectively, “forward-looking statements”). The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and readers are cautioned not to put undue reliance on them. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “can,” “will,” “likely,” “potential,” “occur,” “projects,” “predicts,” “continue,” “goal,” “objective,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “could,” “should,” “would,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers’ expansion into Japan, the anticipated benefits of the acquisition of Eucalyptus, the expected timing and potential launch of new products or offerings, and assumptions relating to the foregoing. These forward-looking statements are based on management’s current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to the integration of Eucalyptus; our ability to successfully expand into new markets or specialties; our ability to launch new products or offerings on expected timelines or at all; expectations regarding market acceptance, user experience and customer retention; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; the impact of general economic, business, or financial conditions; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission as well as additional risks and uncertainties inherent to Hims & Hers’ business, not currently known by Hims & Hers, that are out of Hims & Hers’ control or that Hims & Hers currently deems to be immaterial, which could also have a material adverse effect on Hims & Hers or on its ability to successfully integrate the acquisition of Eucalyptus. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of the date of this press release. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. If Hims & Hers updates any one or more forward-looking statements, no inference should be drawn that Hims & Hers will make additional updates with respect to those forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260602317273/en/ Press Contact
Susan Cadrecha
press@forhims.com Original: Hims & Hers Completes Acquisition of Eucalyptus, Parent Company of Juniper, Officially Entering Japanese Market

Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health PlatformJune 2, 2026 5:00 AM
Business Wire The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims & Hers Health, Inc. (NYSE: HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. Continuing to expand internationally will enable Hims & Hers to lead the next era of digital health, delivering personal, affordable care to more people around the world. This global expansion reinforces the company’s confidence in its long-term targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602132728/en/The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims & Hers can now reach hundreds of millions of people across four continents, bringing more data points into the company's closed-loop ecosystem and expanding the network effects of the platform globally. With this scale, data, and local clinical expertise, the company can deliver access to care that is both deeply personal and clinically rigorous, while maintaining consistent quality worldwide. By pairing personalized treatment with high-touch support, Hims & Hers helps customers stick to their treatment plans longer and achieve better outcomes than with medication alone, making the company a critical partner for healthcare innovators looking to bring new treatments and services to customers around the world. "The future of health isn’t inside of a doctor’s office. It will be integrated into the rhythm of your daily life, anticipating issues before you even see them, and adapting with you,” said Andrew Dudum, co-founder and CEO of Hims & Hers. "Welcoming the Eucalyptus team into Hims & Hers gives us the foundation to become an everyday health companion to people all over the world and a partner to other healthcare innovators who want to build long-term relationships with consumers." Eucalyptus brings deep regional presence and a customer-first digital experience that has served more than 850,0001 customers to date, alongside a proven ability to launch and scale in new markets with clinical rigor and local regulatory expertise. Combined with Hims & Hers' platform, technology infrastructure, and growing portfolio of specialties, these capabilities position the company to deliver care that reflects the needs, regulations, and expectations of each market, while raising the bar for what consumer healthcare can look like globally. "Building Eucalyptus has shown us that the best healthcare is local in its understanding and global in its ambition," said Tim Doyle, Senior Vice President of International at Hims & Hers and former CEO of Eucalyptus. "Joining Hims & Hers gives our teams in Australia, Canada, Germany, Japan, and the United Kingdom the ability to deepen what we've built for our customers, and to bring that experience to many more people in the years ahead." The transaction closed pursuant to the terms of the definitive agreement. 1 As of May 2026. Customer defined as a user having purchased a program through a Eucalyptus brand. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com. Cautionary Note Regarding Forward-Looking Statements Certain statements contained herein are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "assume," "may," "will," "likely," "potential," "projects," "predicts," "continue," "goal," "strategy," "future," "forecast," "target," "outlook," "opportunity," "project," "confidence," "foundation," "groundwork," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the integration of the Eucalyptus business, the international expansion plans of Hims & Hers Health, Inc. (the “Company”), the anticipated impact of the acquisition on the Company's platform capabilities, customer reach, and global network effects, and the Company's long-term financial targets. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained herein are based on the current expectations, assumptions and beliefs of the Company. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: (i) risks related to the integration of the Eucalyptus business, including the ability to successfully combine operations, retain key personnel, and realize the anticipated strategic and financial benefits of the acquisition; (ii) risks related to the Company's international expansion, including challenges in managing operations across multiple jurisdictions and the ability to launch and scale in new markets; (iii) regulatory, compliance, and legal risks in the jurisdictions where the Company operates or plans to operate, including evolving healthcare, consumer protection, and data privacy regulatory frameworks; (iv) risks related to customer adoption and retention across new and existing markets; (v) the Company's ability to achieve its long-term financial targets, which depend on a number of factors including continued growth of the Company's subscriber base, successful integration and expansion of international operations, and broader macroeconomic conditions; and (vi) risks related to the Company's liquidity and capital allocation, including unanticipated demands on cash resources or changes in operating performance, as well as those factors described in the Risk Factors and other sections of the Company's most recently filed Quarterly Report on Form 10-Q, the Company's most recently filed Annual Report on Form 10-K, and other current and periodic reports the Company files from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The Company undertakes no obligation (and expressly disclaims any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. View source version on businesswire.com: https://www.businesswire.com/news/home/20260602132728/en/ Press Contact
Abby Reisinger-Moley
press@forhims.com Original: Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform

Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health PlatformJune 2, 2026 5:00 AM
Business Wire Entering Australia for the first time, Hims & Hers will combine scale, technology, and clinical expertise to make personalised, whole-body care more accessible to every Australian Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus – the parent company of Juniper, Pilot, Kin, and Software – advancing its position as the world's largest consumer health platform and marking its official entry into Australia. This milestone puts the full weight of Hims & Hers’ technology, data, and clinical infrastructure behind a platform that has already transformed how over half a million Australians have accessed care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602264452/en/Entering Australia for the first time, Hims & Hers will combine scale, technology, and clinical expertise to make personalised, whole-body care more accessible to every Australian Over a quarter of Australians continue to face longer than normal wait times for appointments, having to navigate significant health challenges without adequate support. Since 2019, Eucalyptus has served over 550,0001 Australians through a portfolio of brands, addressing some of the country’s most common and underserved health needs, ranging from weight management and reproductive care to men’s sexual health. Through this acquisition, Hims & Hers brings additional resources and operational expertise, giving more Australians access to personalised, evidence-based care for the conditions that matter most to them. "Australians are among the most health-conscious consumers in the world, and Eucalyptus has already begun redefining what healthcare access can look like,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “Now our opportunity is to expand on that foundation, help more people tackle the health challenges that Australians face every day under a unified platform, and deliver access to the kind of whole-body, preventive care Australians deserve.” A local clinical approach remains integral to how Hims & Hers operates in Australia. Customers will continue to be connected with Australian providers who understand the healthcare landscape they are navigating, bringing the local expertise and clinical rigour this kind of care demands. For customers already receiving care through Juniper, Pilot, Kin, or Software, treatment continues uninterrupted. Joining Hims & Hers gives the team the resources and reach to keep building on a model customers have come to trust, with more behind it than ever before. "We built Eucalyptus in Australia because we believed Australians deserved better. More personalised, more proactive, more accessible care," said Tim Doyle, Senior Vice President of International at Hims & Hers and former CEO of Eucalyptus. "More than half a million customers around the world proved us right. Now, through this acquisition by Hims & Hers, an Australian idea drives a global movement forward, one that will reach more people, go deeper than ever before, and change what healthcare looks like everywhere." ____________________ 1 As of May 2026. Customer defined as a user having purchased a program through a Eucalyptus brand. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalised care designed for results. For more information, please visit www.hims.com and www.forhers.com. About Eucalyptus Eucalyptus builds and operates a house of digital healthcare companies. Founded in 2019 by Tim Doyle, Benny Kleist, Alexey Mitko and Charlie Gearside, it is now Australia's largest digital health provider and one of Australia's fastest growing companies. Eucalyptus has facilitated nearly two million consultations across Australia, the UK, Germany, Japan, and Canada, and is the first telehealth company in Australia accredited by the Australian Council on Healthcare Standards (ACHS) against the EQuIP6 standards for safety and quality of clinical services. For more information, visit Eucalyptus's website or follow their page on LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and “forward-looking information” within the meaning of applicable Australian securities legislation (collectively, “forward-looking statements”). The forward-looking statements contained in this press release are expressly qualified by this cautionary statement and readers are cautioned not to put undue reliance on them. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assume,” “may,” “can,” “will,” “likely,” “potential,” “occur,” “projects,” “predicts,” “continue,” “goal,” “objective,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “project,” “confidence,” “foundation,” “groundwork,” or “could,” “should,” “would,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers’ expansion into Australia, the anticipated benefits of the acquisition of Eucalyptus, the expected timing and potential launch of new products or offerings, and assumptions relating to the foregoing. These forward-looking statements are based on management’s current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to the integration of Eucalyptus; our ability to successfully expand into new markets or specialties; our ability to launch new products or offerings on expected timelines or at all; expectations regarding market acceptance, user experience and customer retention; changes in healthcare, consumer protection or privacy laws; increased scrutiny from regulators; the impact of general economic, business, or financial conditions; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission as well as additional risks and uncertainties inherent to Hims & Hers’ business, not currently known by Hims & Hers, that are out of Hims & Hers’s control or that Hims & Hers currently deems to be immaterial, which could also have a material adverse effect on Hims & Hers or on its ability to successfully integrate the acquisition of Eucalyptus. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of the date of this press release. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. If Hims & Hers updates any one or more forward-looking statements, no inference should be drawn that Hims & Hers will make additional updates with respect to those forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this press release. View source version on businesswire.com: https://www.businesswire.com/news/home/20260602264452/en/ Press Contact
Susan Cadrecha
press@forhims.com Original: Hims & Hers Completes Acquisition of Eucalyptus, Advancing Position as the World's Largest Consumer Health Platform

Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness PartnersMay 28, 2026 12:00 PM
Business Wire From connected fitness and cycle tracking to meal delivery and glucose monitoring, Hims & Hers subscribers now have ten ways to support their whole-body health Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, and connected wellness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528501192/en/ Together, the program now offers subscribers 10 ways to access the tools and innovations that support whole-body health, all in one place. The expansion reflects Hims & Hers' ongoing commitment to investing in the subscription experience, ensuring that Hims & Hers delivers meaningful value well beyond the personalized treatment plans available through the platform. “Healthcare is most powerful when your treatment, your data, your nutrition, and your fitness all work together toward the same goal," said Dheerja Kaur, Chief Product Officer at Hims & Hers. "Hims & Hers Benefits are an expression of that belief. By pairing clinical expertise and personalized treatment plans with access to best-in-class health and wellness tools, we're creating a membership experience that goes beyond traditional care — one that supports every dimension of whole-body health, seamlessly, in one place.” Hims & Hers Benefits will continue to grow, with plans to add new partners across every dimension of whole-body health. The program now features ten leading brands spanning nutrition, fitness, women's health, metabolic monitoring, and connected wellness. Today’s new Benefits include: AI coaching that maximizes GLP-1 results with iFIT. Exercise is a powerful complement to GLP-1 treatment — and iFIT makes it personal. Its AI-powered coaching adapts to your fitness data, building science-backed workouts around your specific goals so you can see results faster and build habits that last. Subscribers can get their first three months free ($59.97 value). Build real strength with Ladder. Ladder takes the guesswork out of fitness with expert-programmed strength workouts, built-in progress and nutrition tracking, and coaching that evolves as you do, all in one app. Subscribers receive the first three months free (an $89.97 value). Track food, exercise, and calories with MyFitnessPal. Understanding what you eat is one of the most powerful tools for lasting change. MyFitnessPal makes it effortless with fast logging AI tools, customized meal plans, exercise tracking, and weight all in one place. Hims & Hers subscribers can receive 15% off the annual Premium+ subscription. Eat better, without the effort, with HelloFresh. Healthy eating starts with what's in your kitchen. HelloFresh delivers chef-designed recipes and fresh, pre-portioned ingredients straight to your door, making it easier to cook well even on your busiest nights. Subscribers receive eleven free meals. Nourish your body with Factor. When time is tight but nutrition matters, Factor delivers fresh, never frozen meals that are ready to eat in minutes — no prep, no compromise. Built on real, whole ingredients and free of refined sugars, seed oils, and artificial sweeteners, every dietitian-designed Factor meal is as nutritious as it is convenient. Subscribers can receive 50% off their first box plus free breakfast items for a full year. Track your periods, ovulation, pregnancy, perimenopause and more with Flo Health. Flo transforms health data into personalized, clinical-grade insights, tracking a woman’s cycle, ovulation, and hormonal patterns through every stage of her life with the kind of nuance that adapts as their body changes. It's the #1 women's health app in the world. Subscribers can receive 40% off their subscription. Take control of your reproductive health with Natural Cycles°. The only FDA-cleared women’s health app powerful enough to prevent pregnancy, Natural Cycles uses body temperature data to deliver personalized, clinically validated insights across every phase of a woman’s cycle. Subscribers can receive 28 days of complimentary access to the NC° app, with the flexibility to connect an existing compatible wearable or use the included NC° Band. Move better, for longer, with PVOLVE Studios. Built on a method that uniquely combines the three pillars of longevity training: strength, mobility, and stability. Using patented resistance equipment and functional movement patterns, PVOLVE sculpts and tones the body, while building deeper mind-body awareness helping members move better, longer. Subscribers can receive discounts on in-studio classes. Stelo by Dexcom, is a small, wearable glucose biosensor worn on the back of the upper arm. Designed for adults 18 and older not using insulin, Stelo is the first FDA-cleared glucose biosensor available without a prescription in the U.S. Built on Dexcom’s most accurate glucose sensing technology,1 Stelo gives you real-time insight into how food, movement, stress, and sleep affect your glucose, helping you make smarter, more informed decisions every day. Stelo is available as part of Hims & Hers Benefits for eligible subscribers. Sign in for member benefit details. ____________________ 1 Dexcom, Data on file, 2024 2 Stelo, User Guide, 2024 Underpinning the company’s commitment to put its customers first, Hims & Hers does not profit from these benefits. Instead, 100% of the negotiated benefits are passed directly to active subscribers. *See full terms and conditions at hims.com/benefits and forhers.com/benefits. Active Hims & Hers subscribers can access these benefits immediately. Stelo Safety Information: For full information on risks and benefits, visit stelo.com. About Hims & Hers Health, Inc Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260528501192/en/Press Contact
Susan Cadrecha
press@forhims.com Original: Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners

Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform InvestmentMay 18, 2026 11:59 PM
Business Wire Proceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operational infrastructure to drive anticipated cost efficiencies, and enhances the consumer experience with AI and its closed-loop data ecosystem. Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $350 million aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $300 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on May 21, 2026, subject to customary closing conditions. Hims & Hers also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5 million aggregate principal amount of notes. Hims & Hers intends to use the net proceeds from the offering to preserve financial flexibility while executing on its international expansion strategy, including its proposed acquisition of Eucalyptus, which is expected to close in mid-2026, subject to customary closing conditions. The Company also intends to use the net proceeds to invest in technology and fulfillment infrastructure to drive anticipated cost efficiencies, as well as to scale AI capabilities that enhance the consumer experience and better leverage the Company’s closed-loop data ecosystem. A portion of the net proceeds will be used to fund the cost of entering into the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, a portion of the additional proceeds will also be used to fund the cost of entering into the related capped call transactions. The Company intends to use the remainder of the net proceeds, if any, for general corporate purposes. The notes will be senior, unsecured obligations of Hims & Hers. The notes will not bear regular interest, and the principal amount of the notes will not accrete. The notes will mature on June 1, 2032, unless earlier repurchased, redeemed or converted. Before March 1, 2032, noteholders will have the right to convert their notes only upon the occurrence of certain events. From and after March 1, 2032, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Hims & Hers will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock or a combination of cash and shares of its Class A common stock, at the Company’s option. The initial conversion rate is 33.8590 shares of Class A common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $29.53 per share of Class A common stock. The initial conversion price represents a premium of approximately 32.5% over the last reported sale price of $22.29 per share of the Company’s Class A common stock on May 18, 2026. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at the Company’s option at any time, and from time to time, on or after June 6, 2029 and on or before the 25th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of the Company’s Class A common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid special interest and additional interest, if any, to, but excluding, the redemption date. If a “fundamental change” (as defined in the indenture for the notes) occurs, then, subject to a limited exception, noteholders may require Hims & Hers to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid special and additional interest, if any, to, but excluding, the applicable repurchase date. Hims & Hers estimates that the net proceeds from the offering will be approximately $338.5 million (or approximately $389.5 million if the initial purchasers fully exercise their option to purchase additional notes), after deducting the initial purchasers’ discounts and commissions and the Company’s estimated offering expenses. Hims & Hers intends to use approximately $32.0 million of the net proceeds to fund the cost of entering into the capped call transactions described below. In connection with the pricing of the notes, Hims & Hers entered into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates and/or one or more other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to the Company’s Class A common stock upon any conversion of the notes and/or offset any potential cash payments Hims & Hers is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. The cap price of the capped call transactions will initially be approximately $50.15 per share, which represents a premium of approximately 125% over the last reported sale price of the Company’s Class A common stock of $22.29 per share on May 18, 2026, and is subject to certain adjustments under the terms of the capped call transactions. If the initial purchasers exercise their option to purchase additional notes, then Hims & Hers expects to enter into additional capped call transactions with the option counterparties. In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to the Company’s Class A common stock and/or purchase shares of the Company’s Class A common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of the Company’s Class A common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Company’s Class A common stock and/or purchasing or selling the Company’s Class A common stock or other securities of Hims & Hers in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so (x) during any observation period related to a conversion of notes or following any repurchase of notes by Hims & Hers in connection with any redemption or fundamental change or (y) following any other repurchase of notes by the Company if the Company elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or decrease in the market price of the Company’s Class A common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration that noteholders will receive upon conversion of the notes. The offer and sale of the notes and any shares of Class A common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Class A common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About Hims & Hers Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. Forward-Looking Statements Except for historical information, certain statements in this press release, including statements regarding the completion of the offering, the expected amount and intended use of the net proceeds, the timing of the closing of the proposed Eucalyptus transaction, and the effects of entering into the capped call transactions described above, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business, including, without limitation, risks and uncertainties related to market conditions, the satisfaction of the closing conditions related to the offering, risks related to obtaining the requisite consents to the proposed Eucalyptus transaction, including, without limitation, the timing (including possible delays) and receipt of regulatory approvals from governmental entities (including any conditions, limitations or restrictions placed on these approvals) and the risk that one or more governmental entities may deny approval, and risks relating to international expansion and the Company’s business and strategy. Hims & Hers may not consummate the offering described in this press release and, if the offering is consummated, cannot provide any assurances regarding its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Hims & Hers does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the “Risk Factors” section in the Company’s most recently filed Quarterly Report on Form 10-Q and its most recently filed Annual Report on Form 10-K. View source version on businesswire.com: https://www.businesswire.com/news/home/20260518180060/en/ Investor Relations
Bill Newby
Investors@forhims.com Media Relations
Abby Reisinger-Moley
Press@forhims.com Original: Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

Hims & Hers Shares Slide After Convertible Notes Offering Announcement (HIMS)May 18, 2026 10:01 AM
IH Market News Stock Drops Following Financing Plan Shares of Hims & Hers Health (NYSE:HIMS) fell 7% on Monday after the company revealed plans to issue $300 million of convertible senior notes due in 2032 to qualified institutional investors. Company Targets Expansion and Infrastructure Investment Hims & Hers said the proceeds from the offering are intended to maintain financial flexibility as it pursues its international growth strategy, including the proposed acquisition of Eucalyptus, which is expected to close in mid-2026.The telehealth company also plans to direct capital toward technology upgrades and fulfillment infrastructure aimed at improving cost efficiency and expanding its artificial intelligence capabilities. Details of the Convertible Notes The notes will be senior unsecured obligations carrying interest payments on a semi-annual basis and are scheduled to mature on June 1, 2032.Investors holding the notes will have the ability to convert them under certain conditions. Hims & Hers may settle conversions using cash, Class A common shares, or a combination of both.The company also granted the initial purchasers an option to acquire up to an additional $45 million of notes within 13 days following issuance. Capped Call Transactions Intended to Limit Dilution Hims & Hers said part of the proceeds will be used to finance capped call transactions, which are designed to reduce potential dilution to holders of Class A common stock if the notes are converted.The notes will become redeemable at the company’s option beginning June 6, 2029, if the share price of its Class A stock trades above 130% of the conversion price for a specified period.Meanwhile, noteholders will have the right to require the company to repurchase the notes for cash if certain fundamental change events take place.Hims & Hers stock price Original: Hims & Hers Shares Slide After Convertible Notes Offering Announcement (HIMS)

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform InvestmentMay 18, 2026 7:16 AM
Business Wire Proceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operational infrastructure to drive anticipated cost efficiencies, and enhances the consumer experience with AI and its closed-loop data ecosystem. Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45 million aggregate principal amount of notes. Hims & Hers intends to use the net proceeds from the offering to preserve financial flexibility while executing on its international expansion strategy, including its proposed acquisition of Eucalyptus, which is expected to close in mid-2026, subject to customary closing conditions. The Company also intends to use the net proceeds to invest in technology and fulfillment infrastructure to drive anticipated cost efficiencies, as well as to scale AI capabilities that enhance the consumer experience and better leverage the Company’s closed-loop data ecosystem. A portion of the net proceeds will be used to fund the cost of entering into the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, a portion of the additional proceeds will also be used to fund the cost of entering into the related capped call transactions. The Company intends to use the remainder of the net proceeds, if any, for general corporate purposes. The notes will be senior, unsecured obligations of Hims & Hers, will accrue interest payable semi-annually in arrears and will mature on June 1, 2032, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Hims & Hers will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock or a combination of cash and shares of its Class A common stock, at the Company’s option. The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at the Company’s option at any time, and from time to time, on or after June 6, 2029 and on or before the 25th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of the Company’s Class A common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If certain corporate events that constitute a “fundamental change” occur, then, subject to a limited exception, noteholders may require Hims & Hers to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. In connection with the pricing of the notes, Hims & Hers expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates and/or one or more other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to the Company’s Class A common stock upon any conversion of the notes and/or offset any potential cash payments Hims & Hers is required to make in excess of the principal amount of converted notes, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional notes, then Hims & Hers expects to enter into additional capped call transactions with the option counterparties. In connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to the Company’s Class A common stock and/or purchase shares of the Company’s Class A common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of the Company’s Class A common stock or the notes at that time. In addition, the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to the Company’s Class A common stock and/or purchasing or selling the Company’s Class A common stock or other securities of Hims & Hers in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so (x) during any observation period related to a conversion of notes or following any repurchase of notes by Hims & Hers in connection with any redemption or fundamental change or (y) following any other repurchase of notes by the Company if the Company elects to unwind a corresponding portion of the capped call transactions in connection with such repurchase). This activity could also cause or avoid an increase or decrease in the market price of the Company’s Class A common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period related to a conversion of notes, it could affect the number of shares and value of the consideration that noteholders will receive upon conversion of the notes. The offer and sale of the notes and any shares of Class A common stock issuable upon conversion of the notes have not been, and will not be, registered under the Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of Class A common stock issuable upon conversion of the notes, nor will there be any sale of the notes or any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful. About Hims & Hers Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. Forward-Looking Statements Except for historical information, certain statements in this press release, including statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offering, the intended use of the proceeds, the timing of the closing of the proposed Eucalyptus transaction, and the anticipated terms of, and the effects of entering into, the capped call transactions described above, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and are subject to risks, uncertainties and assumptions about Hims & Hers and its business, including, without limitation, risks and uncertainties related to market conditions, including market interest rates, the trading price and volatility of the Company’s Class A common stock, risks related to obtaining the requisite consents to the proposed Eucalyptus transaction, including, without limitation, the timing (including possible delays) and receipt of regulatory approvals from governmental entities (including any conditions, limitations or restrictions placed on these approvals) and the risk that one or more governmental entities may deny approval, and risks relating to international expansion and the Company’s business and strategy. Hims & Hers may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding the final terms of the offering or the notes or its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Hims & Hers does not undertake to update the statements included in this press release for subsequent developments, except as may be required by law. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the “Risk Factors” section in the Company’s most recently filed Quarterly Report on Form 10-Q and its most recently filed Annual Report on Form 10-K. View source version on businesswire.com: https://www.businesswire.com/news/home/20260517417885/en/ Investor Relations
Bill Newby
Investors@forhims.com Media Relations
Abby Reisinger-Moley
Press@forhims.com Original: Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

The $59B Quiet Shift Reshaping How Patients Access CareMay 12, 2026 10:30 AM
PR Newswire (US) Issued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /PRNewswire/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and five names sit at the center of that structural realignment: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Hims & Hers Health (NYSE: HIMS), Novo Nordisk (NYSE: NVO), MannKind (NASDAQ: MNKD), and Ginkgo Bioworks (NYSE: DNA).  The trajectory keeps steepening. Analysts project the global POC diagnostics market will reach $114.65 billion by 2035, fueled by AI integration, miniaturized biosensors, and cloud-connected platforms that compress turnaround times from days to minutes[3]. The entire diagnostic equipment value chain is shifting from a centralized hospital model to a decentralized, consumer-facing landscape, and that creates a scalable opening for platforms delivering accessible, clinical-grade outcomes outside traditional hospital walls.VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is heading to Europe next week to showcase its AI-powered cardiac imaging platform at one of the biggest cardiology conferences on the planet. The company will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), running May 12 to 16 in Padua, Italy, alongside European distributor AngioPro. AEPC is the world's largest association in congenital cardiology, with over 1,000 specialists across 32 countries, and this year's program is centered on cardiovascular imaging and artificial intelligence, exactly the areas where VentriPoint operates.VMS+™ 4.0 takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to cardiac MRI, but without the million-dollar machine or the months-long wait list. Built on more than a decade of proprietary Knowledge Based Reconstruction technology, the system works with ultrasound equipment from any manufacturer and holds regulatory approvals in the United States, Canada, and Europe.That regulatory footprint is expanding. In late April, VentriPoint announced that strategic partner Lishman Global Inc. formally submitted VMS+™ 4.0 to China's National Medical Products Administration (NMPA) for approval. Lishman Global qualified for the NMPA's expedited "green channel" review pathway, reserved for innovative technologies addressing significant clinical needs. China has an estimated 330 million patients affected by cardiovascular disease.Commercial momentum has been building. VentriPoint recently picked up a Gold Medal at the 2026 Edison Awards for VMS+™ 4.0. It announced a collaboration with the Health Division of the Montecristo Group to deploy VMS+™ across Costa Rica's hospital networks, where Hospital Metropolitano has an existing relationship with Sanford Health. VentriPoint also recently partnered with First Light Health to bring cardiac diagnostics to Indigenous and remote communities across Canada, building on an earlier partnership with the Nisga'a Valley Health Authority. The company also signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California."AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it," said Hugh MacNaught, President and CEO of VentriPoint. "VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI, giving clinicians the confidence they need to manage their patients at every stage of life."With regulatory submissions advancing in China, distribution partners spanning Costa Rica to Northern California, Edison Award recognition, and a growing presence at major cardiology conferences, VentriPoint is building the kind of global footprint that turns a promising medtech platform into a scalable business.CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/Other industry developments and happenings in the market include:Hims & Hers Health (NYSE: HIMS) announced a new collaboration with Novo Nordisk to make a broad assortment of FDA-approved GLP-1 medications available to eligible customers, including Wegovy, the only FDA-approved GLP-1 weight loss pill. The expansion positions Hims & Hers Health as the largest global consumer health platform for affordable access to approved medications, with prices starting as low as $149 a month."Today we're taking an important next step toward building a better model of healthcare that works for everyday people," said Andrew Dudum, co-founder and CEO of Hims & Hers Health. "When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we're thrilled to be working alongside Novo Nordisk to help more people feel their best and we're excited to find more ways to collaborate across the industry."Novo Nordisk (NYSE: NVO) is expanding patient reach through the partnership, with eligible customers now able to access treatments that can help them lose up to 20% of their body weight. Multiple Wegovy dosing options are available across both injectable and pill formats, alongside Ozempic injection pens approved for Type 2 diabetes treatment."Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient," said Dr. Craig Primack, SVP Weight Management at Hims & Hers Health. "As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We're excited to see how our customers succeed as more innovative treatments become available."MannKind (NASDAQ: MNKD) announced it will present new clinical data on Afrezza at the ATTD 2026 conference in Barcelona, spanning oral and poster sessions focused on real-world dosing patterns and post-prandial glucose management in both adult and pediatric patients with type 1 diabetes. The presentations include findings from the INHALE-1 study, which examined how inhaled insulin is initiated and adjusted in children and adolescents, with patients started at an approximately 2:1 conversion from rapid-acting insulin analogs."We look forward to presenting important new data for Afrezza at this year's ATTD and contributing to the scientific dialogue around meal-time diabetes management across both adult and pediatric populations," said Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head, Diabetes for MannKind. "ATTD is a key forum for advancing how clinicians think about insulin use at meals, and we value the opportunity to engage with the global diabetes community on this important topic."The FDA accepted a supplemental Biologics License Application for Afrezza in patients ages 4-17 living with type 1 or type 2 diabetes, with a PDUFA target action date of May 29, 2026. If approved, Afrezza would become the first needle-free insulin option for pediatric patients in over 100 years.Ginkgo Bioworks (NYSE: DNA) launched Ginkgo Cloud Lab, a browser-based interface that gives researchers remote access to the company's autonomous lab infrastructure powered by proprietary Reconfigurable Automation Carts. The platform connects scientists to a fleet of over 70 instruments spanning sample preparation, liquid handling, analytical readouts, storage, and incubation, with an AI-driven agent called EstiMate enabling protocol submission in plain language and immediate compatibility assessment and pricing."Autonomous labs are poised to scale and accelerate the high-mix work that a lab bench supports," said Jason Kelly, CEO of Ginkgo Bioworks. "By opening up our autonomous infrastructure through the Cloud Lab, we're giving scientists access to these tools today."Ginkgo Cloud Lab is central to Ginkgo Bioworks' 2026 strategic shift to consolidate all R&D services onto Nebula, its autonomous lab in Boston, MA, decommissioning traditional benches in favor of programmable robotic infrastructure. The company is targeting users ranging from academic researchers to global biopharmaceutical companies, inviting them to submit protocols directly at cloud.ginkgo.bio for feasibility reports and price quotes.Further Reading: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/CONTACT:
Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.mordorintelligence.com/industry-reports/point-of-care-diagnosticshttps://www.medtechdive.com/news/digital-health-funding-concentrates-fewer-startups-q1-2026-rock-health/816933/ https://www.globenewswire.com/news-release/2026/04/30/3285062/0/en/Global-Point-of-Care-Diagnostics-Market-Size-Set-to-Reach-USD-114-65-Billion-by-2035-SNS-Insider.html Logo: https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg View original content:https://www.prnewswire.com/news-releases/the-59b-quiet-shift-reshaping-how-patients-access-care-302769492.html Original: The $59B Quiet Shift Reshaping How Patients Access Care

Hims & Hers (HIMS) Shares Slide After Surprise First-Quarter LossMay 12, 2026 9:01 AM
IH Market News Shares of Hims & Hers (NYSE:HIMS) dropped roughly 16% in premarket trading on Tuesday after the company reported an unexpected first-quarter loss, missing Wall Street earnings expectations as weaker performance in its U.S. business weighed on results.Hims & Hers posted a net loss of $92.1 million, or $0.40 per share, for the first quarter of 2026, compared with net income of $49.5 million, or $0.20 per share, in the same period last year.Analysts had expected the company to report a profit of approximately $0.01 per share. Revenue Growth Slows as U.S. Sales Decline Quarterly revenue increased 4% year-on-year to $608.1 million from $586.0 million in the prior-year quarter.However, revenue still came in below analyst expectations of $616.5 million.The company’s American operations were a key drag on performance, with U.S. revenue declining 8% year-on-year to $529.9 million.Adjusted EBITDA fell 51% from a year earlier to $44.3 million, missing analyst estimates by roughly 5.5%, according to Morgan Stanley.The earnings report marked the company’s first EBITDA miss since becoming public.Gross margin also weakened, contracting 360 basis points year-on-year to 69.9%, excluding certain charges.“Management has an ambitious strategy that’s prioritizing growth and will require patience on margins. This was the first time it missed on EBITDA and GM continues to trend lower,” Morgan Stanley analyst Craig Hettenbach said in a note. GLP-1 Strategy Shift Impacts Margins Earlier this year, Hims & Hers launched a copy version of Novo Nordisk’s Wegovy pill but later withdrew the product following legal action from Novo and heightened regulatory scrutiny.The company has since shifted strategy and is now working with Novo Nordisk to distribute branded GLP-1 treatments, while agreeing to discontinue its own lower-cost and higher-margin alternatives.“In the first quarter, we made a strategic pivot that expanded our assortment of branded GLP-1 products, and early demand signals show our consumer reach broadening meaningfully,” said Yemi Okupe, Chief Financial Officer.“With nearly 2.6 million subscribers across a diverse breadth of specialties, we have the scale to invest in technology and operations to leverage our closed-loop ecosystem,” Okupe added. Company Raises Revenue Forecast but Cuts EBITDA Outlook Despite the weaker earnings performance, Hims & Hers increased its full-year 2026 revenue guidance, citing expectations for stronger demand across its personalized healthcare offerings.The company now expects annual revenue between $2.8 billion and $3.0 billion, compared with its previous forecast range of $2.7 billion to $2.9 billion.At the same time, management reduced its EBITDA outlook by approximately 7.5%.Hims & Hers now expects full-year EBITDA at a midpoint of roughly $312.5 million.Hims & Hers stock price Original: Hims & Hers (HIMS) Shares Slide After Surprise First-Quarter Loss

Hims & Hers Health, Inc. Reports First Quarter 2026 Financial ResultsMay 11, 2026 4:05 PM
Business Wire Revenue of approximately $608 million, up 4% year-over-year in Q1 2026 Subscribers grew to nearly 2.6 million, up 9% year-over-year in Q1 2026 Raises full year 2026 revenue guidance1 to a range of $2.8 billion to $3.0 billion and updates Adjusted EBITDA guidance to a range of $275 million to $350 million Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings release, and supplemental materials. “2026 is a defining year for Hims & Hers. We’re not just growing, we’re pulling away from the field on our path to becoming the world’s largest consumer health platform,” said Andrew Dudum, co-founder and CEO. “As we exit the first quarter, our domestic business is accelerating, we’re expanding into new categories and countries, and more people than ever are relying on us for access to personal, data-driven care. We’re investing with conviction in comprehensive diagnostics and a technology infrastructure built to make every interaction smarter than the last. The demand for a simpler, more personal path to feeling great has never been stronger, and Hims & Hers is increasingly the answer.” “In the first quarter, we made a strategic pivot that expanded our assortment of branded GLP-1 products, and early demand signals show our consumer reach broadening meaningfully," said Yemi Okupe, Chief Financial Officer. "With nearly 2.6 million subscribers across a diverse breadth of specialties, we have the scale to invest in technology and operations to leverage our closed-loop ecosystem. This will allow us to elevate the subscriber experience and positions us to achieve an industry-leading cost structure. We expect growth to accelerate from here, and have high conviction in our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.”   Key Business Metrics (In Thousands, Except for Monthly Revenue per Average Subscriber, Unaudited)       Three Months Ended March 31,     2025   2025   % Change Subscribers (end of period)     2,584     2,366   9 % Monthly Revenue per Average Subscriber   $ 80   $ 85   (6 )%   __________________________________ 1 Our second quarter and full year 2026 outlook excludes any potential contributions from the recently announced proposed acquisition of Eucalyptus, which is expected to close during the middle of calendar year 2026, subject to customary closing conditions, including regulatory approvals.   Revenue (In Thousands, Unaudited)       Three Months Ended March 31,     2025   2025   % Change United States Revenue   $ 529,909   $ 578,692   (8 )% Rest of the World Revenue     78,195     7,318   969 % Total revenue   $ 608,104   $ 586,010   4 % First Quarter 2026 Financial Highlights Revenue was $608.1 million for the first quarter of 2026 compared to $586.0 million for the first quarter of 2025, an increase of 4% year-over-year. Gross margin was 65% for the first quarter of 2026 compared to 73% for the first quarter of 2025. Net loss was $92.1 million for the first quarter of 2026 compared to net income of $49.5 million for the first quarter of 2025. Adjusted EBITDA was $44.3 million for the first quarter of 2026 compared to $91.1 million for the first quarter of 2025. Net cash provided by operating activities was $89.4 million for the first quarter of 2026 compared to $109.1 million for the first quarter of 2025. Free Cash Flow was $53.0 million for the first quarter of 2026 compared to $50.1 million for the first quarter of 2025. Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net (loss) income and net cash provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States (“U.S. GAAP”), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading “Non-GAAP Financial Measures”. Financial Outlook2 Hims & Hers is providing the following guidance: For the second quarter 2026, we expect: Revenue of $680 million to $700 million. Adjusted EBITDA of $35 million to $55 million, reflecting an Adjusted EBITDA margin of 5% to 8%. For the full year 2026, we expect: Revenue of $2.8 billion to $3.0 billion. Adjusted EBITDA of $275 million to $350 million, reflecting an Adjusted EBITDA margin of 10% to 12%. The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA. __________________________________ 2 Our second quarter and full year 2026 outlook excludes any potential contributions from the recently announced proposed acquisition of Eucalyptus, which is expected to close during the middle of calendar year 2026, subject to customary closing conditions, including regulatory approvals. Conference Call Hims & Hers will host a conference call to review the first quarter 2026 results on May 11, 2026, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link. About Hims & Hers Health, Inc. Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results. For more information, please visit investors.hims.com. Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions; changes in our product or offering mix, and the timing and market acceptance of any new products or offerings; the timing and anticipated effect of any pending or recently completed acquisitions; the success and utility of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”). Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of May 11, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods. Key Business Metrics Our consolidated revenue primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services, primarily consisting of medical consultation services, post-consultation service support, and delivery of laboratory testing results, as applicable. Our online sales are net of refunds, credits, and chargebacks, and include revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. The majority of our online sales are subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. This revenue also includes sales from customers who have made one-time purchases. Additionally, in the United States, we offer a range of health and wellness products through wholesale partners as a way of generating brand awareness with new customers in physical environments and on third-party platforms, with such revenue not considered material to our business. “United States Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States. “Rest of the World Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States. “Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers. “Monthly Revenue per Average Subscriber” is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.   CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Share and Per Share Data, Unaudited)     March 31, 2026   December 31, 2025         Assets       Current assets:       Cash and cash equivalents $ 222,266     $ 228,616   Short-term available-for-sale investments   528,609       348,876   Receivables, net   149,620       32,149   Inventory   79,073       80,128   Prepaid expenses and other current assets   65,795       77,869   Total current assets   1,045,363       767,638   Long-term available-for-sale investments   —       351,263   Goodwill   342,838       278,325   Property, equipment, and software, net   333,845       311,930   Intangible assets, net   261,034       196,116   Operating lease right-of-use assets   144,247       137,046   Deferred tax assets, net   92,091       82,707   Other long-term assets   47,625       29,680   Total assets $ 2,267,043     $ 2,154,705   Liabilities and stockholders' equity       Current liabilities:       Accounts payable $ 306,865     $ 143,278   Accrued liabilities   90,743       78,518   Deferred revenue   165,132       127,160   Earn-out payable   40,096       46,986   Earn-out liabilities   10,362       3,646   Operating lease liabilities   5,579       4,843   Total current liabilities   618,777       404,431   Convertible senior notes, net   974,106       972,580   Operating lease liabilities   152,352       143,167   Earn-out payable   26,944       —   Earn-out liabilities   12,287       53,009   Deferred tax liabilities, net   23,511       28,856   Other long-term liabilities   12,899       11,734   Total liabilities   1,820,876       1,613,777   Commitments and contingencies       Stockholders' equity:       Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 222,326,117 and 218,867,898 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of March 31, 2026 and December 31, 2025   23       23   Additional paid-in capital   656,436       652,383   Accumulated other comprehensive (loss) income   (4,405 )     2,294   Accumulated deficit   (205,887 )     (113,772 ) Total stockholders' equity   446,167       540,928   Total liabilities and stockholders' equity $ 2,267,043     $ 2,154,705     CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (In Thousands, Except Share and Per Share Data, Unaudited)       Three Months Ended March 31,       2026       2025   Revenue   $ 608,104     $ 586,010   Cost of revenue     211,317       155,321   Gross profit     396,787       430,689   Gross margin %     65 %     73 % Operating expenses:(1)         Marketing     222,003       231,235   Operations and support     96,503       63,033   Technology and development     46,936       29,914   General and administrative     109,668       48,610   Total operating expenses     475,110       372,792   (Loss) income from operations     (78,323 )     57,897   Other (expense) income:         Change in fair value of equity securities     (9,682 )     —   Change in fair value of liabilities     (17,646 )     —   Other income, net     4,100       2,598   Total other (expense) income, net     (23,228 )     2,598   (Loss) income before income taxes     (101,551 )     60,495   Benefit from (provision for) income taxes     9,436       (11,010 ) Net (loss) income     (92,115 )     49,485   Other comprehensive (loss) income     (6,699 )     160   Total comprehensive (loss) income   $ (98,814 )   $ 49,645             Net (loss) income per share attributable to common stockholders:         Basic   $ (0.40 )   $ 0.22   Diluted   $ (0.40 )   $ 0.20   Weighted average shares outstanding:         Basic     228,357,303       221,989,327   Diluted     228,357,303       246,610,232   ______________ (1) Includes stock-based compensation expense as follows (in thousands):   Three Months Ended March 31,       2026     2025 Marketing   $ 2,815   $ 2,774 Operations and support     6,113     3,006 Technology and development     5,990     4,045 General and administrative     21,944     15,033 Total stock-based compensation expense   $ 36,862   $ 24,858   CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands, Unaudited)     Three Months Ended March 31,     2026       2025   Operating activities       Net (loss) income $ (92,115 )   $ 49,485   Adjustments to reconcile net (loss) income to net cash provided by operating activities:       Depreciation and amortization   21,953       8,276   Stock-based compensation   36,862       24,858   Change in fair value of equity securities   9,682       —   Change in fair value of liabilities   17,646       —   Net accretion on securities   (242 )     (693 ) Benefit from deferred taxes   (13,975 )     (890 ) Amortization of debt discount and issuance costs   1,701       —   Non-cash operating lease cost   4,582       1,905   Non-cash acquisition-related costs   6,367       1,030   Non-cash restructuring and other related charges included within cost of revenue   28,462       —   Non-cash other   982       832   Changes in operating assets and liabilities:       Receivables, net   (116,247 )     (864 ) Inventory   (20,303 )     (11,669 ) Prepaid expenses and other current assets   645       (16,375 ) Other long-term assets   (8,364 )     73   Accounts payable   167,643       14,473   Accrued liabilities   10,016       4,351   Deferred revenue   37,980       35,480   Earn-out payable   (2,058 )     —   Operating lease liabilities   (1,861 )     (1,182 ) Net cash provided by operating activities   89,356       109,090   Investing activities       Maturities of available-for-sale investments   93,253       31,342   Proceeds from sales of available-for-sale investments   76,708       —   Purchases of property, equipment, and intangible assets   (29,844 )     (55,327 ) Investment in website development and internal-use software   (6,480 )     (3,711 ) Acquisition of businesses, net of cash acquired   (137,866 )     (5,100 ) Purchases of equity securities   (11,217 )     —   Net cash used in investing activities   (15,446 )     (32,796 ) Financing activities       Proceeds from exercise of vested stock options   5,008       3,928   Payments for taxes related to net share settlement of equity awards   (39,206 )     (25,711 ) Payments for acquisition-related earn-out consideration   (43,682 )     —   Payments for debt issuance costs   —       (1,235 ) Net cash used in financing activities   (77,880 )     (23,018 ) Foreign currency effect on cash and cash equivalents   (2,380 )     243   (Decrease) increase in cash, cash equivalents, and restricted cash   (6,350 )     53,519   Cash, cash equivalents, and restricted cash at beginning of period   228,616       221,440   Cash, cash equivalents, and restricted cash at end of period $ 222,266     $ 274,959   Reconciliation of cash, cash equivalents, and restricted cash       Cash and cash equivalents $ 222,266     $ 273,736   Restricted cash   —       1,223   Total cash, cash equivalents, and restricted cash $ 222,266     $ 274,959   Supplemental disclosures of cash flow information       Cash (received) paid for taxes, net of refunds $ (6,603 )   $ 360   Cash paid for interest   1,050       —   Non-cash investing and financing activities       Purchases of property, equipment, and intangible assets included in accounts payable and accrued liabilities $ 8,828     $ 11,019   Right-of-use asset obtained in exchange for lease liability   9,518       52,459   Contingent consideration and liabilities assumed in connection with acquisition of businesses   24,068       —   Deferred debt issuance costs included in accounts payable and accrued liabilities   —       633   Issuance of common stock in connection with asset acquisition   —       12,760   Common stock to be issued for asset acquisition indemnification holdback   —       6,380     Non-GAAP Financial Measures In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure), each as defined below. We also present Adjusted Gross Profit, Adjusted Marketing, Adjusted Operations and support, Adjusted Technology and development, Adjusted General and administrative (collectively, Adjusted Operating Expenses), and Adjusted Net (Loss) Income (each of which are non-GAAP financial measures). We use Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, Free Cash Flow, Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business. Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net (loss) income before stock-based compensation, restructuring and other related charges that are considered non-recurring, depreciation and amortization, change in fair value of liabilities, legal settlement costs that are considered non-recurring, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), change in fair value of equity securities, payroll tax expense related to stock-based compensation, interest income and expense, net, and income taxes. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue. In the first quarter of 2026, we announced a strategic shift for our United States weight loss offering ("2026 US WL Announcement"). As a result, we evolved our United States weight loss offering to match our global approach towards providing access to branded GLP-1 medications, and offering access to compounded GLP-1 medications through our platform on a limited scale. In connection with the strategic shift, we revised our definition of Adjusted EBITDA to include restructuring and other related charges that are considered non-recurring, as we believe these costs are distinguishable from ongoing operating costs and do not reflect current or expected performance of our ongoing operations. These costs consist of inventory write-downs and third-party costs that were incurred directly as a result of the 2026 US WL Announcement. To the extent that we incur additional restructuring charges and other related charges in connection with the 2026 US WL Announcement in future periods, these costs will be presented consistently with our current presentation. As we did not record any non-recurring restructuring and other related charges in prior quarters, prior period disclosures were not impacted. In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results.   Net (Loss) Income to Adjusted EBITDA Reconciliation (In Thousands, Unaudited)     Three Months Ended March 31,     2026       2025           Revenue $ 608,104     $ 586,010           Net (loss) income   (92,115 )     49,485   Stock-based compensation   36,862       24,858   Restructuring and other related charges   33,488       —   Depreciation and amortization   21,953       8,276   Change in fair value of liabilities   17,646       —   Legal settlement costs   15,000       —   Acquisition and transaction-related costs   13,366       24   Change in fair value of equity securities   9,682       —   Payroll tax expense related to stock-based compensation   2,867       —   Interest income and expense, net   (5,033 )     (2,596 ) (Benefit from) provision for income taxes   (9,436 )     11,010   Adjusted EBITDA $ 44,280     $ 91,057           Net (loss) income as a % of revenue   (15 )%     8 % Adjusted EBITDA margin   7 %     16 % Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. “Free Cash Flow” is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities. Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results. Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation (In Thousands, Unaudited)       Three Months Ended March 31,       2026       2025   Net cash provided by operating activities   $ 89,356     $ 109,090   Purchases of property, equipment, and intangible assets in investing activities     (29,844 )     (55,327 ) Investment in website development and internal-use software in investing activities     (6,480 )     (3,711 ) Free Cash Flow   $ 53,032     $ 50,052   Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income are key performance measures that our management uses to assess our operating performance. Because Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income facilitate internal comparisons of our historical operating performance on a more consistent basis, we use these measures for business planning purposes. “Adjusted Gross Profit” is defined as gross profit adjusted for restructuring and other related charges included within cost of revenue. “Adjusted Marketing” is defined as marketing expense adjusted for stock-based compensation. “Adjusted Operations and support” is defined as operations and support expense adjusted for stock-based compensation and restructuring and other related charges included within operating expenses. “Adjusted Technology and development” is defined as technology and development expense adjusted for stock-based compensation. “Adjusted General and administrative” is defined as general and administrative expense adjusted for stock-based compensation, legal settlement costs, and acquisition and transaction-related costs. “Adjusted Net (Loss) Income” represents Net (Loss) Income adjusted for restructuring and other related charges, legal settlement costs, and acquisition and transaction-related costs, net of related tax effects. Some of the limitations of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income include that they omit certain costs and charges, and therefore do not reflect all expenses that impact the corresponding U.S. GAAP results. In evaluating Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income, you should be aware that in the future we may incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income. When evaluating our performance, you should consider Adjusted Gross Profit, Adjusted Operating Expenses, and Adjusted Net (Loss) Income in addition to, and not as a substitute for, other financial performance measures, including our net (loss) income and other U.S. GAAP results.   Gross Profit to Adjusted Gross Profit Reconciliation (In Thousands, Unaudited)       Three Months Ended March 31,       2026       2025             Revenue   $ 608,104     $ 586,010             Gross Profit     396,787       430,689   Restructuring and other related charges included within cost of revenue     28,462       —   Adjusted Gross Profit   $ 425,249     $ 430,689             Gross margin %     65 %     73 % Adjusted gross margin %     70 %     73 % Operating Expenses to Adjusted Operating Expenses Reconciliation (In Thousands, Unaudited)       Three Months Ended March 31,       2026       2025             Marketing   $ 222,003     $ 231,235   Stock-based compensation     (2,815 )     (2,774 ) Adjusted Marketing   $ 219,188     $ 228,461                 Three Months Ended March 31,       2026       2025             Operations and support   $ 96,503     $ 63,033   Stock-based compensation     (6,113 )     (3,006 ) Restructuring and other related charges included within operating expenses     (5,026 )     —   Adjusted Operations and support   $ 85,364     $ 60,027                 Three Months Ended March 31,       2026       2025             Technology and development   $ 46,936     $ 29,914   Stock-based compensation     (5,990 )     (4,045 ) Adjusted Technology and development   $ 40,946     $ 25,869                 Three Months Ended March 31,       2026       2025             General and administrative   $ 109,668     $ 48,610   Stock-based compensation     (21,944 )     (15,033 ) Legal settlement costs     (15,000 )     —   Acquisition and transaction-related costs     (13,366 )     (24 ) Adjusted General and administrative   $ 59,358     $ 33,553   Net (Loss) Income to Adjusted Net (Loss) Income Reconciliation (In Thousands, Unaudited)       Three Months Ended March 31,     2026   2025           Net (loss) income   $ (92,115 )   $ 49,485 Restructuring and other related charges     33,488       — Legal settlement costs     15,000       — Acquisition and transaction-related costs     13,366       24 Tax effects of adjustments     (13,340 )     — Adjusted Net (Loss) Income   $ (43,601 )   $ 49,509   View source version on businesswire.com: https://www.businesswire.com/news/home/20260511509432/en/ Investor Relations
Bill Newby
Investors@forhims.com Media Relations
Abby Reisinger-Moley
Press@forhims.com Original: Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results

Every ad on tv is wegovy

$HIMS Looking for $16 Here!

Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of DirectorsApril 28, 2026 8:35 AM
Business Wire
If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise


Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company’s 2026 annual shareholder meeting in June.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428343333/en/If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise.
Amoo-Gottfried is a seasoned marketing leader with decades of experience helping global transformative brands change how consumers think about their everyday lives. He served as Chief Marketing Officer at DoorDash and in leadership roles at Meta, where he shaped narratives that made the brands category leaders and set the standard for captivating storytelling on an international scale. He has deep experience at some of the world’s top marketing agencies, including Leo Burnett, Wieden + Kennedy, and Publicis, where he established the company’s first owned agency in Central & West Africa. Amoo-Gottfried also serves on the board of beloved consumer companies, including StitchFix and Vital Farms.


“Kofi has a wealth of experience in building and growing brands that change what people believe is possible in everything from home delivery to human connection,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “At Hims & Hers, we’re transforming the everyday health experience by making it simple, deeply personal, and built for real life. Consumers deserve better from their healthcare and, as we continue working to help millions of people around the world feel great, we believe Kofi is an incredibly valuable nominee to join our board.”


“I believe Hims & Hers is on track to be the next company that becomes a daily companion to people everywhere,” said Kofi Amoo-Gottfried. “The company’s focus on making healthcare not only simple, but a completely reimagined experience, is shifting the entire industry, and I’m honored to be nominated as they begin this next chapter of growth.”


In addition to Amoo-Gottfried, Hims & Hers also nominates the following returning members:



Andrew Dudum, CEO of Hims & Hers



Deb Autor, former FDA deputy and Chief Policy Officer of Hims & Hers



Dr. Toby Cosgrove, former CEO of the Cleveland Clinic



Anja Manuel, international regulatory and foreign policy expert



Christopher Payne, tech industry leader



Andrea Perez, President of FP Movement and former Nike and Sony marketing executive



Käre Schultz, former pharmaceutical industry chief



David Wells, former CFO of Netflix



Additionally, the Company and the Board are grateful to Christiane Pendarvis and Dr. Pat Carroll for their many years of dedicated service. Ms. Pendarvis and Dr. Carroll are not up for re-election at the 2026 annual meeting, and the total size of the board will be decreased to 9, effective as of the election of directors at the annual meeting. Dr. Carroll will continue to serve as the company’s Global Chief Medical Officer.


About Hims & Hers Health, Inc


Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.


Cautionary Note Regarding Forward-Looking Statements


This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “coming,” “starting,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the board of directors and the company’s future growth. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.


Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the results of the shareholder vote at the 2026 annual meeting; changes or developments in the composition of the board of directors; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.


Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of April 28, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260428343333/en/
Press Contact

Abby Reisinger-Moley

press@forhims.com


Original: Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

Hims & Hers jumps 7% after expanding partnership with Eli LillyApril 23, 2026 10:06 AM
IH Market News
Hims & Hers Health (NYSE:HIMS) shares climbed 7% after the company revealed an expansion of its platform that allows healthcare providers to prescribe weight loss treatments from Eli Lilly.The telehealth firm said clinicians using its platform can now issue prescriptions for Zepbound vials, KwikPen, and Foundayo, which can be fulfilled through the LillyDirect pharmacy. The service includes access to self-pay pricing options for Hims & Hers customers and enables licensed providers to connect patients with FDA-approved GLP-1 therapies.



Broader push into GLP-1 treatments



The move builds on a prior announcement last month, when Hims & Hers partnered with Novo Nordisk to offer access to Wegovy injections and oral treatments.The company said these initiatives reflect a broader strategic shift in its U.S. weight loss segment, driven by growing demand and evolving market dynamics around GLP-1 medications.



Expanded care offering for members



Hims & Hers noted that its weight loss program includes a range of support services, such as 24/7 access to care teams, personalized nutrition plans, regular clinical follow-ups, and peer support through its Weight Loss community.



Focus on personalized treatment access



The company added that its goal is to give users access to a wide selection of treatment options, combined with a comprehensive care experience tailored to individual medical history, preferences, and health goals.Hims & Hers stock price

Original: Hims & Hers jumps 7% after expanding partnership with Eli Lilly

Hims & Hers Shares Jump on Proposed FDA Peptide Rule ChangesApril 16, 2026 7:27 AM
IH Market News
Shares of Hims & Hers Health Inc (NYSE:HIMS) surged 11% in premarket trading on Thursday, extending gains after a 14% rise in the previous session.The upward move came after comments from Health and Human Services Secretary Robert F. Kennedy Jr., who indicated that the Food and Drug Administration is in the process of removing 12 peptides from Category 2 restrictions.Back in 2025, Hims & Hers expanded its capabilities by acquiring a manufacturing facility in California, aiming to grow its range of peptide-based treatments, including products focused on weight management and muscle recovery.Hims & Hers stock price

Original: Hims & Hers Shares Jump on Proposed FDA Peptide Rule Changes

Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026April 13, 2026 4:05 PM
Business Wire
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.


The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year.


Upcoming Conference Participation


Hims & Hers also announced that members of the company’s management team will be participating in the Evercore TMT Conference on June 2, 2026 in San Francisco.


About Hims & Hers Health, Inc.


Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.


We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.


For more information, please visit https://investors.hims.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260413335848/en/
Investor Relations


Bill Newby

Investors@forhims.com


Media Relations


Abby Reisinger-Moley

Press@forhims.com


Original: Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & HersMarch 26, 2026 12:00 PM
Business Wire
Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill


Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk’s FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy® pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims & Hers is making it simpler for customers to access FDA-approved GLP-1 medications which are now available at more affordable prices, with more doses and delivery methods. This expansion makes Hims & Hers the largest global consumer health platform for affordable access to approved medications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326503294/en/Starting today, eligible customers can access a broad assortment of treatment options, including the only FDA-approved GLP-1 weight loss pill.
Based on an independent provider’s clinical decision, eligible Hims & Hers customers can now access Novo Nordisk treatments that can help them lose up to 20% of their body weight.2 Medication options include Wegovy® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg injection and 1.5 mg, 4 mg, 9 mg, and 25 mg pills, with Wegovy® (semaglutide) 7.2 mg injection coming soon. Ozempic® (semaglutide) 0.25 mg, 0.5 mg, 1 mg, and 2 mg injection pens, which are approved as treatments for Type 2 diabetes, will also be available for eligible patients based on individual clinical judgment. Ozempic is not FDA-approved for weight loss. Prices start as low as $149 a month.3


“Today we’re taking an important next step toward building a better model of healthcare that works for everyday people,” said Andrew Dudum, co-founder and CEO of Hims & Hers. “When healthcare innovators work together, we can make sure customer access moves at the same speed as innovation. As the largest global consumer health platform, we’re thrilled to be working alongside Novo Nordisk to help more people feel their best and we’re excited to find more ways to collaborate across the industry.”


“Obesity medications have evolved over the last several years to become more affordable, more flexible, and more approachable for every kind of patient,” said Dr. Craig Primack, SVP Weight Management at Hims & Hers. “As a part of our comprehensive treatment program, these FDA-approved medications will help more people get and stay healthy. We’re excited to see how our customers succeed as more innovative treatments become available.”


The company is also introducing a new membership for weight loss, which will include comprehensive support services, 24/7 direct access to providers, personalized nutrition guidance, ongoing clinical check-ins, as well as peer support in the Hers Weight Loss community. Membership starts at $39 for the first month, $149 each month after.4 Medication costs are separate and may be covered under the customer’s HSA and FSA plan. All Hims & Hers subscribers have access to special savings.


Customers will be educated on this expanding assortment of FDA-approved medications, and if determined clinically appropriate by their providers, will be given the opportunity to transition seamlessly to those medications. For what is anticipated to be a limited set of customers whose clinical needs cannot be met using the increasingly varied set of commercially available FDA-approved GLP-1s, Hims & Hers plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary.


For more information, visit www.hims.com/weight-loss or www.forhers.com/weight-loss.


About Hims & Hers Health, Inc


Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.


Disclaimers


This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding the offerings and services accessible on our platform, including their diversity, efficacy, pricing, dosages, and timing of availability; the quotes from our CEO and SVP, Weight Management; statements regarding the education of our customers on a broad assortment of FDA-approved medications and the potential transition to such medications; statements regarding our plans to offer access to compounded GLP-1s if a provider determines that a compounded product is clinically necessary and the expectation that such customer set will be limited; statements regarding future collaborations or expanded access to treatment options; and statements regarding the membership model, including pricing thereof and what it is expected to include. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.


Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to updating access to the semaglutide offerings available on our platform (branded and compounded), and the related customer response; the timing or feasibility of potential future partnerships or collaborations or expanded access to treatment options available on our platform; risks related to our international expansion efforts, including any pending or completed acquisitions, and the timing, integration and performance thereof; changes in the application, interpretation, and enforcement of healthcare, consumer protection or privacy laws or regulations applicable to our business; the timing, outcome or impact of this announcement on ongoing litigation, governmental actions or regulatory statements; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission. In addition, at this time we cannot predict or estimate the impact any collaboration with Novo Nordisk and / or the impact any shift in our GLP-1 business may have on our future results, including revenue or EBITDA.


Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of March 26, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.


1 Not available in all 50 states. Prescription required. Weight Loss by Hims & Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions. Wegovy® is a registered trademark of Novo Nordisk A/S.

2 In separate clinical studies of adults with overweight or obesity, about 1 in 4 taking Wegovy® oral semaglutide 25 mg (64 weeks), about 1 in 3 taking Wegovy® injection 2.4 mg (68 weeks), and about 1 in 2 taking Wegovy® injection 7.2 mg (72 weeks) lost ≥20% of body weight, alongside diet and exercise. Average weight loss was approximately 14–19%. Individual results may vary. Stopping treatment may result in weight regain.

3 Membership required, fee not included, and billed separately.

4 Price includes membership fee only. Membership is billed separately and does not include or guarantee a prescription. Medication is not available without a membership.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326503294/en/
Press Contact

Abby Reisinger-Moley

press@forhims.com


Original: Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

Back to 70

Up 2 dollars

Hims & Hers Health stock continues rally, rises 7% in premarket tradingMarch 12, 2026 7:02 AM
IH Market News
Shares of Hims & Hers Health (NYSE:HIMS) climbed as much as 7.2% in premarket trading on Thursday, building on a 10% surge recorded during Wednesday’s session. The stock is now on track to post gains for a fourth consecutive day.By the close of trading on Wednesday, the company’s shares had already surged about 64% for the week, putting the stock on course for its strongest weekly performance on record.The sharp rally began on Monday after reports that Novo Nordisk plans to distribute its weight-loss medications through the Hims platform, boosting investor optimism around the company’s growth prospects.Hims & Hers stock price

Original: Hims & Hers Health stock continues rally, rises 7% in premarket trading

Lilly flags impurity in compounded versions of its weight-loss drug, warns of potential health risksMarch 12, 2026 7:01 AM
IH Market News
Eli Lilly (NYSE:LLY) said compounded weight-loss treatments that combine vitamin B12 with the active ingredient used in its Zepbound drug may pose health risks because of a newly identified impurity formed during preparation, according to a public letter released by the U.S. pharmaceutical company on Thursday.The letter, based on Lilly’s testing of compounded products, marks the company’s latest effort to challenge drug compounders that it says are producing and marketing unauthorized copies of Zepbound and its diabetes therapy Mounjaro. Both medicines contain the same active ingredient, tirzepatide.Lilly has filed lawsuits against compounding pharmacies, wellness clinics and other businesses accused of selling products advertised as containing tirzepatide.Compounders, however, have argued that their formulations are permitted under a specific federal law provision that allows customized drug compounding when patients require personalized treatment, such as adding vitamins or providing doses not available in the branded medicines.Testing conducted by Lilly on samples obtained from compounding pharmacies, medspas and telehealth providers found “significant levels of an impurity that results from a chemical reaction between tirzepatide and B12,” according to the letter and a scientific paper describing the testing process that was shared with Reuters.The company said the impurity appeared in all ten samples analyzed during the testing.“Nothing is known about its short- or long-term effects in humans, the potential impact on the drug’s interaction with the GLP-1 and GIP receptors, toxicity, immune reactions, or how it is absorbed, distributed, metabolized, and eliminated,” said the letter, which was published on Lilly’s website.“FDA (the U.S. Food and Drug Administration) warns that compounded products can be risky for patients because they are not reviewed for safety, effectiveness, or quality. Adding a reactive substance like vitamin B12 without clinical testing or FDA review introduces additional unknown risks,” said David Hyman, Lilly’s chief medical officer.Lilly said it had informed the FDA about the findings and urged regulators to issue a nationwide recall for products that contain both tirzepatide and vitamin B12.In September, the FDA sent warning letters to 30 telehealth companies over what it described as false or misleading claims about compounded weight-loss medications.The agency has also warned it could take action against what it called “illegal copycat drugs” after telehealth firm Hims & Hers Health (NYSE:HIMS) said in February that it planned to sell a compounded version of Novo Nordisk’s Wegovy pill.Hims later reversed course on the compounded product and announced this week that it plans to offer Novo’s Wegovy and Ozempic through its platform instead.Eli Lilly stock priceHims & Hers stock price

Original: Lilly flags impurity in compounded versions of its weight-loss drug, warns of potential health risks

$HIMS-Onboard nice records once closing adding more I on $HIMS right forward longer concatenated morning were accompaniment for gainers alot going on in minds we are forwards?

Moving nicely glad I brought 16

Hims & Hers Names Kathryn Beiser as Chief Communications OfficerMarch 10, 2026 8:08 PM
Business Wire
The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world’s leading consumer health platform in its next phase of growth


Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company’s expansive vision for the future.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310539680/en/The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world’s leading consumer health platform in its next phase of growth.
A seasoned communications leader, Beiser has expertise launching, building, and elevating corporate brands in highly regulated industries, serving as the Chief Communications Officer for companies including Discover, Kaiser Permanente, and, most recently, Eli Lilly and Company, and the head of the global corporate practice Edelman. She specializes in guiding companies through transformative growth phases, helping them articulate their vision and connect authentically with customers, investors, and other key stakeholders.


“From my very first conversations with the team at Hims & Hers, I saw an incredible opportunity to work with smart, values-driven leaders who are passionate about putting customers first,” said Beiser. “It’s such a privilege to be working with this visionary team during the next phase of the company’s growth trajectory. We have such an exciting story to tell as we help more and more people around the world feel great.”


"We’re on a journey to build the most beloved and trusted brand in the world and Kathy will play an integral role in accomplishing that ambition. She is the communications leader we need for this moment,” said Andrew Dudum, CEO and Co-Founder of Hims & Hers. "She is a passionate, roll-up-her-sleeves kind of leader who brings a rare combination of deep industry experience, communications expertise, and the energy to bring our story to life.”


About Hims & Hers Health, Inc.


Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310539680/en/
Press Contact:

Abby Reisinger-Moley

press@forhims.com


Original: Hims & Hers Names Kathryn Beiser as Chief Communications Officer

Hims & Hers Shares Jump on Analyst Upgrades After Novo Nordisk PartnershipMarch 10, 2026 11:44 AM
IH Market News
Hims & Hers Health (NYSE:HIMS) shares climbed about 10% on Tuesday, extending Monday’s sharp rally of nearly 49% after analysts upgraded the stock following the company’s newly announced partnership with Novo Nordisk (NYSE:NVO).The collaboration, unveiled Monday, enables Hims & Hers to offer commercially available doses of Ozempic and Wegovy—including a newly developed pill formulation—as part of an expanded weight-loss treatment strategy centered on GLP-1 therapies. As part of the agreement, Novo Nordisk has also withdrawn its lawsuit against Hims & Hers.BofA Securities analyst Allen Lutz upgraded the stock from Underperform to Neutral and raised his price target to $23.00 from $12.50. The revised valuation reflects a 23x CY26E EV/EBITDA multiple that now factors in expected GLP-1-related revenue.Citi analyst Daniel Grosslight also lifted his rating to Neutral and increased his price target to $24 from $13.25. Grosslight noted that the agreement requires Hims & Hers to end its mass-personalization model, allowing only a limited group of customers to remain on compounded GLP-1 treatments. He also said Novo Nordisk dropping the lawsuit “significantly diminishes legal risk.”Earlier, Needham analyst Ryan MacDonald upgraded the stock from Hold to Buy with a $30.00 price target, saying the partnership removes key legal overhangs and materially reshapes the company’s weight-loss strategy and long-term growth outlook.The agreement also allows Hims & Hers to offset potential revenue losses tied to compounded GLP-1 medications by replacing them with branded offerings through its partnership with Novo Nordisk, although the company will face tighter limits on its compounding operations.Hims & Hers shares finished Monday’s session at $22.16.Hims & Hers stock priceNovo Nordisk stock price

Original: Hims & Hers Shares Jump on Analyst Upgrades After Novo Nordisk Partnership

U.S. stocks tumble as oil rally fueled by Middle East conflict rattles marketsMarch 9, 2026 11:44 AM
IH Market News
U.S. equities opened sharply lower on Monday as escalating tensions in the Middle East pushed oil prices toward $100 a barrel, intensifying concerns that rising energy costs could pressure economic growth.As of 09:43 ET, the S&P 500 declined 1.2% to 6,655.57, the Nasdaq Composite dropped 1.3% to 22,103.06, and the Dow Jones Industrial Average fell 1.4% to 46,846.08.Wall Street had already ended the previous week on a negative note, with all three major indexes posting losses of at least 1% as investors grew increasingly worried that the widening conflict in the Middle East could weigh on global economic activity.



Oil surge fuels inflation and growth concerns



Monday’s selloff came as crude oil prices surged following an escalation in hostilities involving the United States, Israel and Iran over the weekend.Brent crude futures for May delivery climbed 8% to $100.12 per barrel, while U.S. benchmark West Texas Intermediate rose 7.7% to $97.78 per barrel amid concerns about potential supply disruptions and risks to tanker traffic through the Strait of Hormuz, one of the world’s most important oil shipping routes.The sharp rise in energy prices has renewed fears that a fresh oil shock could push inflation higher while also dampening consumer spending in the United States.A prolonged rise in crude prices could complicate the Federal Reserve’s policy outlook by sustaining inflationary pressures even as signs emerge that economic growth may be slowing.International Monetary Fund Managing Director Kristalina Georgieva warned that a sustained 10% increase in oil prices could lift global headline inflation by roughly 0.4 percentage points.Speaking during a keynote address at an event in Japan, Georgieva said: “Think of the unthinkable and prepare for it.”The market reaction also follows last week’s release of weaker-than-expected February nonfarm payrolls data, which raised fresh concerns about the strength of the U.S. labor market.While Monday’s economic calendar is relatively light, investors are preparing for several key data releases later in the week. The U.S. consumer price index will be published on Wednesday, followed by the Federal Reserve’s preferred inflation gauge—the personal consumption expenditures price index—on Friday, along with data on job openings.



Iran names Mojtaba Khamenei as new supreme leader



The conflict in the Middle East showed little sign of easing after Iran named Mojtaba Khamenei as the country’s new supreme leader following the assassination of his father, Ali Khamenei.Mojtaba, widely viewed as a hardliner and described by U.S. President Donald Trump as “unacceptable”, is expected to continue Iran’s confrontational stance toward Western countries.Trump also commented on the surge in oil prices Sunday evening, saying the increase was an acceptable consequence of military action targeting Iran’s nuclear program, even as rising fuel costs began to affect U.S. gasoline prices.Meanwhile, NATO spokesperson Allison Hart said Monday that the alliance had intercepted another missile headed toward Turkey.



Hims & Hers shares soar after Novo Nordisk report



In corporate developments, Hewlett Packard Enterprise is scheduled to release quarterly results after the close on Monday. Earnings from Kohl’s, Oracle, Dollar General and Dick’s Sporting Goods are also expected later this week.Separately, Bloomberg reported that Novo Nordisk plans to distribute its weight-loss drugs through the telehealth platform operated by Hims & Hers Health, signaling a potential reconciliation between the companies after a recent legal dispute.Shares of Hims & Hers Health (NYSE:HIMS), which have declined about 51% so far this year, surged more than 40% on Monday following the report.Hims & Hers stock price

Original: U.S. stocks tumble as oil rally fueled by Middle East conflict rattles markets

Hims surges 44% after report Novo Nordisk may offer weight-loss drugs on its platformMarch 9, 2026 6:49 AM
IH Market News
Novo Nordisk (NYSE:NVO) is planning to distribute its weight-loss medications through the telehealth platform operated by Hims & Hers Health (NYSE:HIMS), signaling an unexpected thaw in relations between the companies after a recent legal clash, Bloomberg reported over the weekend.Shares of Hims — which have fallen roughly 51% so far this year — jumped more than 44% in premarket trading Monday as of 09:08 GMT. Meanwhile, Novo Nordisk’s shares in Copenhagen rose about 1%.According to the report, the companies could unveil a new partnership as soon as Monday. The arrangement would allow Novo’s obesity treatments to be sold through Hims’ platform, restoring a relationship that broke down last year after Novo accused the telehealth provider of continuing to promote compounded versions of its medications.The renewed collaboration follows months of escalating tensions. In February, Novo filed a lawsuit against Hims after the telehealth company introduced a copycat version of its oral Wegovy weight-loss pill, arguing the product violated patents linked to the active ingredient used in its blockbuster drugs Ozempic and Wegovy.Leerink analyst Michael Cherny said the development was “both a surprise and an unabashed positive for HIMS’ stock,” noting that it could help avoid what had appeared likely to become “a protracted legal process that could include a full trial.”Still, Cherny cautioned that “even with this positive news, we do not see this as a clearing event for HIMS to fully recapture its growth potential and thus maintain our Market Perform rating.”In a separate research note, Morgan Stanley analyst Craig Hettenbach said a partnership between the companies could remove one of the biggest uncertainties hanging over the stock — legal and regulatory risks related to the company’s weight-loss offerings. He added that “any reduction in those risks could lead to a strong rebound in the heavily shorted stock.”During recent supply shortages, telehealth providers such as Hims sold lower-cost compounded versions of weight-loss treatments developed by Novo Nordisk and Eli Lilly. Although those shortages have since been resolved and companies were expected to halt the sale of such copies, some providers have continued offering them by adjusting dosages or altering ingredients to distinguish them from the branded drugs, the report said.Novo Nordisk stock priceHims & Hers stock price

Original: Hims surges 44% after report Novo Nordisk may offer weight-loss drugs on its platform

Hims & Hers shares fall after softer-than-expected first-quarter outlookFebruary 24, 2026 5:58 AM
IH Market News
Shares of telehealth provider Hims & Hers Health (NYSE:HIMS) dropped more than 6% in U.S. premarket trading on Tuesday, pressured partly by weaker-than-anticipated guidance for the current quarter.The company expects first-quarter 2026 revenue to come in between $600 million and $625 million, below analyst consensus forecasts of $653.9 million. Adjusted EBITDA for the period is projected in a range of $35 million to $55 million.For the full year 2026, Hims & Hers guided revenue of $2.7 billion to $2.9 billion, broadly in line with consensus expectations of $2.75 billion. Adjusted EBITDA is anticipated to reach between $300 million and $375 million.“1Q26 guidance implies a meaningful sequential ramp over the course of 2026. Notably, management expects [year-on-year] growth in both Weight Loss and non-Weight Loss businesses in 2026. The after-market trading […] likely reflects limited visibility beyond 1Q,” analysts at Truist Securities said in a note.Fourth-quarter earnings per share totaled $0.08, exceeding analyst estimates of $0.05. Revenue reached $617.8 million, slightly below consensus expectations of $618.7 million, while subscriber numbers increased 13% year-on-year to 2.5 million.The results arrive as the stock continues to face pressure linked to regulatory scrutiny and intensifying competition within the weight-loss treatment market.After a government ban on bulk sales of copycat drugs, Hims & Hers shifted toward offering more personalised formulations based on the active ingredient used in Novo Nordisk’s Wegovy. However, the company’s attempt to introduce lower-cost compounded versions of Wegovy at an introductory price of $49 per month was halted earlier this month after the U.S. Food and Drug Administration warned it could pursue legal action against the company and similar providers. Hims & Hers is also dealing with lawsuits filed by Novo.According to a Reuters report, short interest in Hims & Hers reached its highest level in at least a year in January. The company’s shares have declined more than 53% so far in 2026 and are down over 69% over the past 12 months.Hims & Hers stock price

Original: Hims & Hers shares fall after softer-than-expected first-quarter outlook

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 23, 2026 4:05 PM
Business Wire
Revenue of approximately $2.35 billion, up 59% year-over-year in 2025


Net income of $128 million; Adjusted EBITDA of $318 million in 2025


Subscribers grew to over 2.5 million, up 13% year-over-year in 2025


Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million


Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com.


“More than 2.5 million subscribers now rely on us for a healthcare experience that is both accessible and deeply personal – and we believe we’re well on our way to becoming the global leader in consumer health,” said Andrew Dudum, co-founder and CEO. “In 2025, we made it possible for more customers across the world to depend on us for access to care across an expanding range of conditions. From launching hormone therapies and diagnostics, introducing Labs to unlock deeper health insights, and taking meaningful steps to grow internationally, the investments we’re making today position us to set a new standard in healthcare for people everywhere. The continued growth and diversification of our platform is helping to create a world where proactive, preventative, and personalized care can feel like a luxury without actually costing like one.”


“Our financial results in 2025 demonstrate the power of scaling a deeply personalized consumer health platform,” said Yemi Okupe, Chief Financial Officer. “Revenue grew 59% year-over-year to $2.35 billion as we expanded our subscriber base and increased engagement across specialties by bringing new sources of value to millions of customers. With a strong balance sheet and robust operating cash flow from tenured specialties in our domestic operations, we have the flexibility to invest in scaling new specialties, advancing our technology and infrastructure, and expanding internationally, all supporting our path toward our 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA.”




Key Business Metrics




(In Thousands, Except for Monthly Revenue per Average Subscriber and Monthly Online Revenue per Average Subscriber, Unaudited)











 



 






 






Three Months Ended

December 31,






 






Year Ended

December 31,








 






 






2025






 






2024






 






% Change






 






2025






 






2024






 






% Change








Subscribers (end of period)






 






 






2,511






 






 






2,229






 






13






%






 






 






2,511






 






 






2,229






 






13






%








Monthly Revenue per Average Subscriber






 






$






83






 






$






75






 






11






%






 






$






83






 






$






65






 






28






%








Monthly Online Revenue per Average Subscriber






 






$






82






 






$






73






 






12






%






 






$






81






 






$






64






 






27






%








_______________



1 Our first quarter and full year 2026 outlook: (1) excludes any potential contributions from the recently announced proposed acquisition of Eucalyptus, which is expected to close during the middle of calendar year 2026, subject to customary closing conditions, including regulatory approvals, and (2) assumes the ongoing ability to provide access to compounded semaglutide through our platform, and no changes to our current business relationships.









Revenue




(In Thousands, Unaudited)











 



 






 






Three Months Ended

December 31,






 






Year Ended

December 31,








 






 






2025






 






2024






 






% Change






 






2025






 






2024






 






% Change








United States Revenue






 






$






554,147






 






$






474,259






 






17






%






 






$






2,213,648






 






$






1,449,671






 






53






%








Rest of the World Revenue






 






 






63,671






 






 






6,880






 






825






%






 






 






133,989






 






 






26,843






 






399






%








Total revenue






 






$






617,818






 






$






481,139






 






28






%






 






$






2,347,637






 






$






1,476,514






 






59






%








 






 






 






 






 






 






 






 






 






 






 






 






 








Online Revenue






 






$






609,113






 






$






470,760






 






29






%






 






$






2,311,449






 






$






1,437,937






 






61






%








Wholesale Revenue






 






 






8,705






 






 






10,379






 






(16






)%






 






 






36,188






 






 






38,577






 






(6






)%








Total revenue






 






$






617,818






 






$






481,139






 






28






%






 






$






2,347,637






 






$






1,476,514






 






59






%







Fourth Quarter 2025 Financial Highlights



Revenue was $617.8 million for the fourth quarter of 2025 compared to $481.1 million for the fourth quarter of 2024, an increase of 28% year-over-year.



Gross margin was 72% for the fourth quarter of 2025 compared to 77% for the fourth quarter of 2024.



Net income was $20.6 million for the fourth quarter of 2025 compared to $26.0 million for the fourth quarter of 2024.



Adjusted EBITDA was $66.3 million for the fourth quarter of 2025 compared to $54.1 million for the fourth quarter of 2024.



Net cash provided by operating activities was $61.3 million for the fourth quarter of 2025 compared to $86.4 million for the fourth quarter of 2024.



Free Cash Flow was $(2.6) million for the fourth quarter of 2025 compared to $59.5 million for the fourth quarter of 2024.



Full Year 2025 Financial Highlights



Revenue was $2,347.6 million for the year ended December 31, 2025 compared to $1,476.5 million for the year ended December 31, 2024, an increase of 59% year-over-year.



Gross margin was 74% for the year ended December 31, 2025 compared to 79% for the year ended December 31, 2024.



Net income was $128.4 million for the year ended December 31, 2025, compared to $126.0 million for the year ended December 31, 2024, which was impacted by the change in valuation allowance of $68.0 million due to the release of the valuation allowance on our domestic deferred tax assets, partially offset by tax activity for that period.



Adjusted EBITDA was $318.0 million for the year ended December 31, 2025 compared to $176.9 million for the year ended December 31, 2024.



Net cash provided by operating activities was $300.0 million for the year ended December 31, 2025 compared to $251.1 million for the year ended December 31, 2024.



Free Cash Flow was $57.4 million for the year ended December 31, 2025 compared to $198.3 million for the year ended December 31, 2024.



Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net income and net cash provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States (“U.S. GAAP”), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading “Non-GAAP Financial Measures”.


Financial Outlook2


Hims & Hers is providing the following guidance:


For the first quarter 2026, we expect:



Revenue of $600 million to $625 million.



Adjusted EBITDA of $35 million to $55 million, reflecting an Adjusted EBITDA margin of 6% to 9%.



For the full year 2026, we expect:



Revenue of $2.7 billion to $2.9 billion.



Adjusted EBITDA of $300 million to $375 million, reflecting an Adjusted EBITDA margin of 11% to 13%.



The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.


We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income or loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income or loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.


Conference Call


Hims & Hers will host a conference call to review the fourth quarter and full year 2025 results on February 23, 2026, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.


About Hims & Hers Health, Inc.


Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.


We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.


For more information, please visit investors.hims.com.



_______________



2 Our first quarter and full year 2026 outlook: (i) excludes any potential contributions from the recently announced proposed acquisition of Eucalyptus, which is expected to close during the middle of calendar year 2026, subject to customary closing conditions, including regulatory approvals, and (ii) assumes the ongoing ability to provide access to compounded semaglutide through our platform, and no changes to our current business relationships.







Cautionary Note Regarding Forward-Looking Statements


This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, and the timing and market acceptance of any new products or offerings, the timing and anticipated effect of any pending or recently completed acquisitions; the success of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.


Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).


Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of February 23, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.


By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.


Key Business Metrics


We continually and strategically review our key business metrics to ensure that they are helpful in managing or monitoring the performance of our business as it grows, which may result in changes in our key business metrics over time. Historically, we have disaggregated our total revenue between Online Revenue and Wholesale Revenue (both defined below). During 2025, as a result of completed acquisitions, we launched operations in the European Union and Canada, and deepened our presence in the United Kingdom. We expect to continue to expand internationally, including in connection with our proposed acquisition of Eucalyptus. As a result, we are now disaggregating our total revenue between United States Revenue and Rest of the World Revenue (both defined below). Online Revenue and Wholesale Revenue have become a less relevant disaggregation of our total revenue, and we anticipate no longer reporting these financial results beginning with the three months ending March 31, 2026. Additionally, Monthly Online Revenue per Average Subscriber (as defined below) has become less relevant for our business. We anticipate no longer reporting this metric beginning with the three months ending March 31, 2026, and are instead reporting Monthly Revenue per Average Subscriber, as defined below.


“United States Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States.


“Rest of the World Revenue” represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States.


“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them. Online Revenue also includes sales from customers who have made one-time purchases.


“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms.


“Subscribers” are customers who have one or more “Subscriptions” pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services. Customers who have made one-time purchases are not considered Subscribers.


“Monthly Revenue per Average Subscriber” is defined as total revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.


“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by Average Subscribers, which amount is then further divided by the number of months in a period.




CONSOLIDATED BALANCE SHEETS




(In Thousands, Except Share and Per Share Data, Unaudited)








 



 






December 31,








 






2025






 






2024








Assets






 






 






 








Current assets:






 






 






 








Cash and cash equivalents






$






228,616






 






 






$






220,584






 








Short-term available-for-sale investments






 






348,876






 






 






 






79,667






 








Inventory






 






80,128






 






 






 






64,427






 








Prepaid expenses and other current assets






 






110,018






 






 






 






31,153






 








Total current assets






 






767,638






 






 






 






395,831






 








Restricted cash






 






—






 






 






 






856






 








Long-term available-for-sale investments






 






351,263






 






 






 






—






 








Goodwill






 






278,325






 






 






 






112,728






 








Property, equipment, and software, net






 






311,930






 






 






 






82,083






 








Intangible assets, net






 






196,116






 






 






 






43,410






 








Operating lease right-of-use assets






 






137,046






 






 






 






10,881






 








Deferred tax assets, net






 






82,707






 






 






 






61,603






 








Other long-term assets






 






29,680






 






 






 






147






 








Total assets






$






2,154,705






 






 






$






707,539






 








Liabilities and stockholders' equity






 






 






 








Current liabilities:






 






 






 








Accounts payable






$






143,278






 






 






$






91,180






 








Accrued liabilities






 






78,518






 






 






 






53,013






 








Deferred revenue






 






127,160






 






 






 






75,285






 








Earn-out payable






 






46,986






 






 






 






—






 








Earn-out liabilities






 






3,646






 






 






 






—






 








Operating lease liabilities






 






4,843






 






 






 






1,889






 








Total current liabilities






 






404,431






 






 






 






221,367






 








Convertible senior notes, net






 






972,580






 






 






 






—






 








Operating lease liabilities






 






143,167






 






 






 






9,456






 








Earn-out liabilities






 






53,009






 






 






 






—






 








Deferred tax liabilities, net






 






28,856






 






 






 






—






 








Other long-term liabilities






 






11,734






 






 






 






—






 








Total liabilities






 






1,613,777






 






 






 






230,823






 








Commitments and contingencies






 






 






 








Stockholders' equity:






 






 






 








Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 218,867,898 and 212,459,586 shares issued and outstanding as of December 31, 2025 and 2024, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2025 and 2024






 






23






 






 






 






22






 








Additional paid-in capital






 






652,383






 






 






 






719,155






 








Accumulated other comprehensive income (loss)






 






2,294






 






 






 






(324






)








Accumulated deficit






 






(113,772






)






 






 






(242,137






)








Total stockholders' equity






 






540,928






 






 






 






476,716






 








Total liabilities and stockholders' equity






$






2,154,705






 






 






$






707,539






 









CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME




(In Thousands, Except Share and Per Share Data, Unaudited)











 



 






 






Three Months Ended December 31,






 






Year Ended December 31,








 






 






2025






 






2024






 






2025






 






2024








Revenue






 






$






617,818






 






 






$






481,139






 






 






$






2,347,637






 






 






$






1,476,514






 








Cost of revenue






 






 






173,383






 






 






 






111,598






 






 






 






614,259






 






 






 






303,379






 








Gross profit






 






 






444,435






 






 






 






369,541






 






 






 






1,733,378






 






 






 






1,173,135






 








Gross margin %






 






 






72






%






 






 






77






%






 






 






74






%






 






 






79






%








Operating expenses:(1)






 






 






 






 






 






 






 






 








Marketing






 






 






238,049






 






 






 






221,085






 






 






 






919,296






 






 






 






678,844






 








Operations and support






 






 






80,073






 






 






 






58,083






 






 






 






286,444






 






 






 






185,802






 








Technology and development






 






 






40,962






 






 






 






23,749






 






 






 






149,301






 






 






 






78,819






 








General and administrative






 






 






76,165






 






 






 






48,028






 






 






 






272,724






 






 






 






167,767






 








Total operating expenses






 






 






435,249






 






 






 






350,945






 






 






 






1,627,765






 






 






 






1,111,232






 








Income from operations






 






 






9,186






 






 






 






18,596






 






 






 






105,613






 






 






 






61,903






 








Other income (expense):






 






 






 






 






 






 






 






 








Change in fair value of equity securities






 






 






4,437






 






 






 






—






 






 






 






4,437






 






 






 






—






 








Change in fair value of liabilities






 






 






(1,629






)






 






 






—






 






 






 






(9,255






)






 






 






—






 








Other income, net






 






 






6,359






 






 






 






3,695






 






 






 






23,129






 






 






 






9,808






 








Total other income, net






 






 






9,167






 






 






 






3,695






 






 






 






18,311






 






 






 






9,808






 








Income before income taxes






 






 






18,353






 






 






 






22,291






 






 






 






123,924






 






 






 






71,711






 








Benefit from income taxes






 






 






2,248






 






 






 






3,734






 






 






 






4,441






 






 






 






54,327






 








Net income






 






 






20,601






 






 






 






26,025






 






 






 






128,365






 






 






 






126,038






 








Other comprehensive income (loss)






 






 






1,373






 






 






 






(553






)






 






 






2,618






 






 






 






(200






)








Total comprehensive income






 






$






21,974






 






 






$






25,472






 






 






$






130,983






 






 






$






125,838






 








 






 






 






 






 






 






 






 






 








Net income per share attributable to common stockholders:






 






 






 






 






 






 






 






 








Basic






 






$






0.09






 






 






$






0.12






 






 






$






0.57






 






 






$






0.58






 








Diluted






 






$






0.08






 






 






$






0.11






 






 






$






0.51






 






 






$






0.53






 








Weighted average shares outstanding:






 






 






 






 






 






 






 






 








Basic






 






 






227,056,624






 






 






 






219,027,485






 






 






 






224,959,268






 






 






 






215,939,037






 








Diluted






 






 






248,096,429






 






 






 






240,725,350






 






 






 






258,230,547






 






 






 






236,808,876






 









______________







(1)


Includes stock-based compensation expense as follows (in thousands):









 






 






Three Months Ended December 31,






 






Year Ended December 31,








 






 






2025






 






2024






 






2025






 






2024








Marketing






 






$






3,185






 






 






$






2,637






 






 






$






12,510






 






 






$






9,392






 








Operations and support






 






 






5,873







 






 






2,743







 






 






18,910







 






 






10,205









Technology and development






 






 






5,106






 






 






 






3,824






 






 






 






19,240






 






 






 






12,534






 








General and administrative






 






 






20,324






 






 






 






15,145






 






 






 






84,584






 






 






 






60,191






 








Total stock-based compensation expense






 






$






34,488






 






 






$






24,349






 






 






$






135,244






 






 






$






92,322






 









CONSOLIDATED STATEMENTS OF CASH FLOWS




(In Thousands, Unaudited)








 



 






Years Ended December 31,








 






2025






 






2024








Operating activities






 






 






 








Net income






$






128,365






 






 






$






126,038






 








Adjustments to reconcile net income to net cash provided by operating activities






 






 






 








Depreciation and amortization






 






54,502






 






 






 






17,088






 








Stock-based compensation






 






135,244






 






 






 






92,322






 








Change in fair value of equity securities






 






(4,437






)






 






 






—






 








Change in fair value of liabilities






 






9,255






 






 






 






—






 








Net accretion on securities






 






(2,032






)






 






 






(4,355






)








Benefit from deferred taxes






 






(12,961






)






 






 






(61,649






)








Impairment of long-lived assets






 






531






 






 






 






114






 








Amortization of debt discount and issuance costs






 






4,529






 






 






 






—






 








Non-cash operating lease cost






 






12,413






 






 






 






2,546






 








Non-cash acquisition-related costs






 






5,893






 






 






 






—






 








Non-cash other






 






(2,135






)






 






 






357






 








Changes in operating assets and liabilities:






 






 






 








Inventory






 






(13,722






)






 






 






(41,612






)








Prepaid expenses and other current assets






 






(51,856






)






 






 






(9,494






)








Other long-term assets






 






(518






)






 






 






(56






)








Accounts payable






 






30,297






 






 






 






43,710






 








Accrued liabilities






 






(43,053






)






 






 






23,791






 








Deferred revenue






 






51,604






 






 






 






67,552






 








Operating lease liabilities






 






(1,913






)






 






 






(2,443






)








Earn-out payable






 






—






 






 






 






(2,825






)








Net cash provided by operating activities






 






300,006






 






 






 






251,084






 








Investing activities






 






 






 








Purchases of available-for-sale investments






 






(725,838






)






 






 






(160,564






)








Maturities of available-for-sale investments






 






108,698






 






 






 






208,940






 








Proceeds from sales of available-for-sale investments






 






—






 






 






 






725






 








Investment in website development and internal-use software






 






(16,546






)






 






 






(11,095






)








Purchases of property, equipment, and intangible assets






 






(226,045






)






 






 






(41,655






)








Acquisition of businesses, net of cash acquired






 






(145,227






)






 






 






(15,399






)








Purchase of equity securities






 






(20,000






)






 






 






—






 








Net cash used in investing activities






 






(1,024,958






)






 






 






(19,048






)








Financing activities






 






 






 








Proceeds from issuance of convertible senior notes, net of debt discount






 






970,000






 






 






 






—






 








Purchases of capped calls related to convertible senior notes






 






(47,800






)






 






 






—






 








Proceeds from exercise of vested stock options






 






11,033






 






 






 






26,651






 








Payments for taxes related to net share settlement of equity awards






 






(116,669






)






 






 






(52,501






)








Repurchases of common stock






 






(89,960






)






 






 






(83,039






)








Proceeds from employee stock purchase plan






 






6,440






 






 






 






3,901






 








Payments for debt issuance costs






 






(3,424






)






 






 






—






 








Payments for acquisition-related earn-out consideration






 






—






 






 






 






(3,190






)








Proceeds from exercise of Class A common stock warrants






 






—






 






 






 






333






 








Net cash provided by (used in) financing activities






 






729,620






 






 






 






(107,845






)








Foreign currency effect on cash and cash equivalents






 






2,508






 






 






 






(270






)








Increase in cash, cash equivalents, and restricted cash






 






7,176






 






 






 






123,921






 








Cash, cash equivalents, and restricted cash at beginning of period






 






221,440






 






 






 






97,519






 








Cash, cash equivalents, and restricted cash at end of period






$






228,616






 






 






$






221,440






 








Reconciliation of cash, cash equivalents, and restricted cash






 






 






 








Cash and cash equivalents






$






228,616






 






 






$






220,584






 








Restricted cash






 






—






 






 






 






856






 








Total cash, cash equivalents, and restricted cash






$






228,616






 






 






$






221,440






 








Supplemental disclosures of cash flow information






 






 






 








Cash paid for taxes






$






23,162






 






 






$






7,916






 








Non-cash investing and financing activities






 






 






 








Purchases of property and equipment included in accounts payable and accrued liabilities






$






25,244






 






 






$






7,781






 








Right-of-use asset obtained in exchange for lease liability






 






132,837






 






 






 






2,593






 








Issuance of common stock in connection with asset acquisition






 






12,760






 






 






 






—






 








Common stock to be issued for asset acquisition indemnification holdback






 






6,380






 






 






 






—






 








Common stock issued, contingent consideration, additional consideration payable, and liabilities assumed in connection with acquisition of businesses






 






200,267






 






 






 






16,000






 








Issuance of common stock for acquisition-related earn-out consideration






 






—






 






 






 






1,396






 







Non-GAAP Financial Measures


In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.


However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.


Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net income before stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee and nonemployee compensation with vesting requirements incurred directly as a result of acquisitions, and (ii) transaction professional services), change in fair value of liabilities, payroll tax expense related to stock-based compensation, impairment of long-lived assets, legal settlement expenses that are considered non-recurring, change in fair value of equity securities, income taxes, and interest income and expense, net. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.


In the second quarter of 2025, we revised our definition of Adjusted EBITDA to include payroll tax expense related to stock-based compensation, which comprises employer taxes incurred upon vesting of restricted stock units and upon exercise of nonqualified stock options. As a result of recent trends in our stock price, this amount was not considered significant for prior periods and, accordingly, prior period disclosures were not recast to conform to the current presentation.


Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income and other U.S. GAAP results.




Net Income to Adjusted EBITDA Reconciliation




(In Thousands, Unaudited)










 



 






Three Months Ended December 31,






 






Year Ended December 31,








 






2025






 






2024






 






2025






 






2024








 






 






 






 






 






 






 






 








Revenue






$






617,818






 






 






$






481,139






 






 






$






2,347,637






 






 






$






1,476,514






 








 






 






 






 






 






 






 






 








Net income






 






20,601






 






 






 






26,025






 






 






 






128,365






 






 






 






126,038






 








Stock-based compensation






 






34,488






 






 






 






24,349






 






 






 






135,244






 






 






 






92,322






 








Depreciation and amortization






 






18,092






 






 






 






6,061






 






 






 






54,502






 






 






 






17,088






 








Acquisition and transaction-related costs






 






3,451






 






 






 






2,155






 






 






 






15,544






 






 






 






3,979






 








Change in fair value of liabilities






 






1,629






 






 






 






—






 






 






 






9,255






 






 






 






—






 








Payroll tax expense related to stock-based compensation






 






1,555






 






 






 






—






 






 






 






6,947






 






 






 






—






 








Legal settlement






 






—






 






 






 






2,008






 






 






 






—






 






 






 






2,008






 








Impairment of long-lived assets






 






—






 






 






 






—






 






 






 






531






 






 






 






114






 








Benefit from income taxes






 






(2,248






)






 






 






(3,734






)






 






 






(4,441






)






 






 






(54,327






)








Change in fair value of equity securities






 






(4,437






)






 






 






—






 






 






 






(4,437






)






 






 






—






 








Interest income and expense, net






 






(6,805






)






 






 






(2,741






)






 






 






(23,526






)






 






 






(10,349






)








Adjusted EBITDA






$






66,326






 






 






$






54,123






 






 






$






317,984






 






 






$






176,873






 








 






 






 






 






 






 






 






 








Net income as a % of revenue






 






3






%






 






 






5






%






 






 






5






%






 






 






9






%








Adjusted EBITDA margin






 






11






%






 






 






11






%






 






 






14






%






 






 






12






%







Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. “Free Cash Flow” is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.


Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results.




Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation




(In Thousands, Unaudited)











 



 






 






Three Months Ended December 31,






 






Year Ended December 31,








 






 






2025






 






2024






 






2025






 






2024








Net cash provided by operating activities






 






$






61,312






 






 






$






86,385






 






 






$






300,006






 






 






$






251,084






 








Less: purchases of property, equipment, and intangible assets in investing activities






 






 






(59,388






)






 






 






(24,520






)






 






 






(226,045






)






 






 






(41,655






)








Less: investment in website development and internal-use software in investing activities






 






 






(4,493






)






 






 






(2,365






)






 






 






(16,546






)






 






 






(11,095






)








Free Cash Flow






 






$






(2,569






)






 






$






59,500






 






 






$






57,415






 






 






$






198,334






 







 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223564900/en/
Investor Relations

Bill Newby

Investors@forhims.com


Media Relations

Abby Reisinger-Moley

Press@forhims.com


Original: Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results